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ABSTRACT
A Newfoundland family. consisting of three nuclear families, was identified as
having polycystic kidneyand liver disease and found to be descended from two founding
ancestral pairs . Using homozygosity mapp ing with polymorphic microsat elli te markers,
three disease loci, ~PH·l . -2 and mouse bpkljcpk were excluded and linked the disease in
sibsbips A and B [0 the ARPKD disease loci on chromosome 6. Due to a meiotic
recombination in one of the individuals in sibship A, the ARPKD critical region was
narrowed to a leM region. The disease in sibship C was not linked to either of the
abovementioned loci and kidney ultrasound suggested that the disease was not ADPKD.
Becausethe genewhich causesARPKDis, as yet. unknown. it was necessary to anempt to
identifyit through positionalcloning. A PAC contiguousmap was constructed to allow the
examination of smaller, indivi dual pieces of DNA within the region. Each clone was
subcloned and screened for microsatellites. Three were identified however none was
variable in this family. The complete sequence of clone l 08c2 bad been published to the
publicdomainand examination revealeda large repeat regionwhichwas analyzedand found
to be polymorphic. This markerallowedthe ARPKDregionto be further refined to an area
of approximately 560kb in size, completely covered by PAC clones. This region contains
10 known gene-oriented clusters representing different transcri pts including NFY~
TFAP2B, MDFIand APOBEC2(bttp:llwww.ncbi.nlm.nib.gov/ UniGene).
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1. INTROD UCTION
1.1 GESETICS AND DI SEASE
Generic diseases are caused by a change in the sequence of DNA, differential
methylation of a DNA strand, or through chromosomal rearrangements. A cbange in
sequence within a gene may result in a chan ge in the transcribed ~"lA and may affect the
resulting protein sequence. Large insertions and deletions wiU significantly alter a gene
product whichcan affect its functionby deleting functional domainsor alteringthestructure
oftbe product Deletions mayalsoaffect proper cellularlocalization, propersplicingor the
rate of transcription if the deletion involves a promoter region. If the gene product
performed an essential function then the mutation may cause systemic manifestations.
Single base pair insertionsor deletions within an exon will cause a cbange in the reading
frameandcause the translated productbe altered or truncated due to the creation of a "SlOP"
codon. resulting in a shortened gene product. Single base pair substitutions, whichdo not
alter the reading frame of the DNA. may cause an altered aminoacid sequence whichcan
changethe function of the protein. A mutation in a noncoding region of the genomemay
also cause disease if the mutation occurs in an area of the genome corresponding to a
regulatory region (Strachan and Read, 1999).
Different diseases are described as baving either a dominantor recessive mode of
inheritance. Dominant inheritanceoccurswhenthediseaseisexpressedwhenonlyone copy
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of thepairof genesis mutated. In thesediseases themutated geneproduct will oftenacquire
an abnormal function, explaining why only one copy of the gene is required to causethe
disease. In recessiveinberitance,on theotherhand,thedisease is expressedonly whenboth
copies of a pair of genes are mutated. In these cases the gene product has often lost an
essential function, thus two mutated genes are required to fully express the disease
phenotype. Usually when onecopyof a mutatedgeneis inherited the othercopy is ableto
compensate for the loss throughincreasedexpression, oftenthrougha feedback loopsystem.
By identifying a gene and the nature of the mutation which causes a disease, it is possible
to predict the mutatedgene product and compareit to the normal product. Oncea genehas
been cloned and tbe function determined, it may then be possible to develop a medical
treatment in order to prevent the diseaseor alleviatethe symptoms.
The type of disease can often be determined by simply examining the pedigree of
affected individuals. The five important Mendelian pedigree patterns are autosomal
dominant,autosomal recessive, X-linkeddominant,X-linked recessive and Y-linked;each
ofwbichissubjecttoa varietyofcomplications. An individual with an autosomaldominant
disease usually hac; at least one affected parent andapproximately 50% oftbe childrenofan
affected individual will inherit thedisease, and affectedindividuals are seen throughoutthe
pedigree in several generations. For autosomal recessive diseases, affected individuals
usually have unaffected parents and appear in a single generation of the pedigree. This is
especially true for marriages in which there is some degree of consanguinity. X-linked
recessive diseases affect mostly males as males arehemizygous for the X chromosome and
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they usually have unaffectedparents. Femalesareaffectedonly if the father is affectedand
the mother is a carrier, but there is never anyfather to son transmission of the disease. X·
linked dominant diseases affect more females than males and half of the offspring of an
affected female will also inherit the disease as there is a 50010 chancethat she will pass the
mutatedchromosometo her offspring. In the caseof an affected male, all of his daughters
will be affected but noneof his sons. This isbecausetheX-chromosome is inheritedbyhis
daughters and only the Y-chromosome is inherited bt his sons. Finally, Ydinked diseases
affectonly males. All affected males havean affectedfather, provided the mutation is not
new (Strachan and Read, 1999). These general patterns can be complicated by such
phenomena as late onset diseases where a disease does not manifest until late in life or
decreasedpeneuance wherenot all individualswhoinherit a mutation developa phenotype.
Genetic research is presently goingthrough a revolution due to the rapid expansion
of sequence data available from public databases. This information allows researchers to
compare their data toother datasetsquickly andeasily. It is nowpossible to takenucleotide
sequence dataof interest andsearch for similar sequences at the nucleotide or protein level,
allowing for the discovery of functional domains or expressed sequences. Homology
searches of genes discovered in simpler organisms have lead to the discoveryof manynew
human genes. Expressed sequence tag and sequence tagged site databases allow for the
identification of transcribed sequences withina region. (Pandey and Lewiner, 1999).
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1.2 FII"DING A DISEASE GENE
1.2.1 Positional Clonin g
Over thepast 20 yearsmanydiseasegenes have been identified by using molecular
cloning techniques, approximately 1677 accordingto theOnline Mendelian Inheritancein
Man (hnp:/Iv.'WW3.ncbi.nlm.nih.gov/OmimJ). "Traditional" methods required tbat some
informationonthegene functionwasknown. Forexamplethegeneforphenylketonuria was
discovered because of'prior knowledge of the biochemicaldeficiency (Robsonet ai., 1992).
However, for the majority of the thousands of generic diseases identified, there is no
functional information available on the nature of the gene product. The technique of
positional cloning allows for the identificationof a disease gene by first identifying a map
position (Collins, 1992a).
The initial step in positionalcloning is the localization of the gene in question to a
relatively small area of the genome. This involves screening large multiplex families in
which there is awell defined phenotype. Polymorphic markersare used to screen theDNA
of the individuals of the family in order to determine the inheritance of each area of the
genome for affected and unaffected individuals in relationto thetrait of interest (Leppert,
1990; Collins,1992b). The polymorphic markers usedare usually simple di- tri- or tetra-
nucleotide repeats whose locations in the genome areknown. These markers. also known
as microsatellite markers. aregenerally foundevery IOOkb throughout thehumangenome
(Dib et al., 1996; The Utah Marker DevelopmentGroup, 1995). The lengthof the repeat is
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quite variable yetrelatively stable within families. Becausethey aremadeupof a repeating
sequence, stem loopsmayformduringreplication andcausethenewly synthesizedDSA to
be either longer or shorter than the original repeat sequence. The markers have unique
sequenceson eitherend of the repeat,allowing for the creation of oligonucleotide primers
which canbe used to amplify and study specific markers.
The only drawbackto this method is the size of the humangenomewhich bas a
haploidsize of three billion nucleotides. This means that98%to 99%of themarkerstested
will Rot be linkedto the gene (Collins,1992b). To dale, merehavebeen 171 diseasegenes
disco vered usin g th e method of pos it ional cl onin g (O MI M,
bnp1/www3.ncbi.nlm.nib.govIOmiml)
1.2.2 HomoZ)'gosit)' 1\.lapping
Duringthe meiosis I phaseofgamete production, followingreplication, membersof
each of the chromosomal pairs, maternal and paternal, come together and align at tbe
metaphase plate of the cell. During anaphase I. the bivalentchromosomes separate and
migrate to opposite poles of the cell prior to division. For each of the 23 pairs of
chromosomes, which homolog endsup in each daughter celI is random. creating8.4 X 106
possible combinations (Strachan and Read, 1999). This satisfies Mendel's law of
independentassortment. HoweverMendel\\'35 unabletopredictthephenomenonofgenetic
recombinationwhichoccursduringgametogenesis. Duringprophaseofmeiosis I, thepaired
bomologous chromatidsrandomly exchange genetic material. Th isexchangeinvolves a
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physical breakin each of the homologouspair of chromosomesand rejoining to the sister
chromosome. Thus, thepaternallyderivedchromosomewill exchange geneticmaterialwith
the maternally derived chromosome. As this processof recombination occurs at ensuing
generations, it is only the most closely linked chromosomal regions which will remain
linked. Identifying tbese regions is the basis for gene mapping and allows geneticists to
refine an area of tbe genome which containsa disease gene.
Individuals with a rarerecessive disease in consanguineous families are likely to be
homozygous for the disease causing mutation as well as for an ancestral haplotype (a
commonset of alleles for markerslinked to the disease locus)becauseof inheritancefrom
a common ancestor. This is known as homozygosity by descent (Ha D) (Lander and
Botstein, 1987). The more remotethe common ancestor, the smaller the shared portionof
the genomebetweenrelatives and thegreater the significance for linkageto a diseasegene
if HBD can be identified (Strachan and Reid, 1999). Homozygosity mapping involves
finding areas of the genome which are HBD in affected individuals but not unaffected
individuals (Strachan and Read, 1997).
Markers are initially used to screensegmentsof the genome identified ascandidate
loci. segments containing potential disease inducing genes. When evidence for
homozygosity among all affected individuals is found for one or more of the polymorphic
markers, thedata are analyzedbycomputer to determine the probability thatthe markersare
linkedto the disease being investigated. This is calculated by determining the probability
that homozygosity of the markersoccur in the affectedindividuals by chanceassuming a
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particular recombination frequency (6). The calculation is then redone assuming that the
markerand gene of interest are linkedand the ratio of the two probabilities (linked and
unlinked at a particular 6) is determined. This ratio, expressed in LogIO' depicts the ratio of
oddsfor andagainst thatdegreeof linkage. This is knownas a LOD<bog ofthe !K!ds) score
and it is expressed as z (Monon, 1955). If z is greater than or equal to 3 it is considered
evidencefor linkage andrepresents a minimum of 1000:1 odds that the loci are linked. A
negative LOD score indicates a recombinationhas occurred between a marker and geneof
interestwhile LODscore s -2 is consideredconclusiveevidence against linkage between a
marker andgene (Thompson et al., 1991andWatsoneral., J992 ). Once linkage with a set
of markers basbeendetermined,the areacontaining the diseasegene. knownas the critical
regionanddefinedby flanking markers, isusually quite large. The next step in the process
is to narrowthe region down as muchas possible. To accomplish this, the region is funber
examinedfor the presence of microsatelIite repeats untilthe area is saturated with a large
number of polymorphic markers. These markers are then used to identify meiotic
recombination events which would define the boundaries of a refined critical region
containing the mutated gene. The critical region can nowbe definedby the smallest area
knownto behomozygousforallaffected individuals and noneoftheunaffectedindividuals.
When the critical region has been sufficiently refined. the next step is to identify
geneswithinthis regionwhichcouJdcausethe disease. TheHumanGenomeProject.whose
goa] it is to completely map the humangenome, can provide useful information on which
genesare ina specific area. However, this projectis farfrom over;not allgenesare mapped
.g,
and the function of other genesare unknown. A workingdraft is expected to be completed
sometime this year. However, the complete reference sequence is not expected until
2003(Francis Collins,Directorof'Nlri, in apublic addressto the 49:1l annuaJmeeringof'<Ibe
American Society of Human Genetics", San Franc isco, USA) . Ther efore. it may not be
possible [0 findthe gene ofi nrerest in any database. On average, a I Mb region ofhwnan
DNA containsapproximately 20 to 30 geneswhich need to be isolated and tested for the
presence of mutations (Fields et al., 1994). This process of identifying 3 geneby location
first and thendiscovering its function, as opposedto beginning with a known gene product
and usingtheamino acidsequence to isolate thegene. is known as positional cloning. The
first gene to be successfully linked to a polymorphic marker with a known locus in the
human genomein this manner was the cystic fibrosis gene (Tsui et aI., 1985)
1.2.3 Physleal Mapp ing
Thegoalofphysicalmappingis to refinea genes's location toa small enoughregion,
usually IcM,so thatall expressedsequencescanbe identified and tested to seewhichis the
gene of interest. To furtherrefine a gene's location, the critical region must first be cloned
using a phage(PAC), bacterial (SAC), cosmid, PI, or yeast artificial chromosome (YAC)
(Neuhausen et aI., 1994; Shizuya et a!. 1992; Feingold et al., 1990; Carrano et al., 1989).
Cosmids are easy to work with; however, the DNA insert which they are able to
accommodate is quite small, only about 40 to 45Kb (Whittakeret al., 19S5). In contrast,
YACs are able toaccommodaterelatively large inserts, consistingof up to I Mb. However,
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they are difficult to work with as they are difficult to grow and a large number of them
undergorecombination(Burkeet al., 1987; Traver et al., 1989). Presently, PACs and Pis
arebetweenYACsand cosmidswhenconsideringadvantagesanddisadvantages. astheyare
quiteeasy to work.with andareableto handlean insertof approximately 120Kb (Sternberg
et al ., 1992; Ioannou et al., 1994) (Fig. I). The D:\A clones art then screened for the
presence of genetic markerswhichare known to mapto the critical region. A clone which
contains a marker that maps to the critical region is isolated and tested with other markers
in order to determine bow much of the critical region the particularclone covers and if it
overlapswith other clones. Overlappingclones contribute to the construction of a physical
map referred to as a contiguousmap, or contig.
Oncethe contigbasbeenproduced, a searchfor individualgeneswithintheareamay
begin. involving the use of one or moretechniques. One techniquecommonly usedis the
screeningof complementary DNA (eDNA)libraries. cDNAlibraries are createdfrom the
mRNA of specific tissue types at a specific age, fetal kidney for example. Expressed
sequencesfroma specific area canbe isolatedby using radiolabeled PAC or YACDNAas
a probe (Lovettet 31., 1991). A more involved technique consistsof sequencing thewhole
areaandperformingagenerecognitionsearchofgenomicdatabases(UberbacherandMural,
1991) . Exontrapping is a technique wherebygenomicfragments arecloned into a plasmid
where the cloning site lies between a splice donor and a splice acceptor flanked by N 'O
knownsequences. Theplasmid is then transfected intoasuitableeukaryoticcell linewhere
thecellularmachinery transcri bes theinsert DNAalongwiththeknownflankingsequences.
·10-
sacS ..-- E. colt Promoter
I~~
5fi Bam Not
~ An ill ustration of the pAd lOsacBII PAC vector d epicting its major features.
Insert D~A is cloned into a BamHl site by SP6 and n sequences which facil itate
sequencing the ends afthe insert. The plasmid also contains a lytic replicon whi ch is
under the control of the Lac promoter. This enables the induction of plasmid synthesis
resulti ng in up to 20 copies percell.
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Once spliced, the unknown exon is trappedbetween two known sequences where is can be
used as a template to makeeDNA. The trapped exon may then be sequenced and analyzed
or it may be used as a probe to search for fulliengtb cDNAs(Duyk et a1.,1990 ). Finally, the
candidategeneapproach involvesdeterminingwhichgeneshavealready beenmappedto the
area of interest, researching their function, and detennining if one of them couldbe the cause
of the disease being studied. This latter approach is important as there have been very few
human disease genes whicb have been isolated solely on the basis of isolation from a
particular area and identification of mutations (papadopoulos, 1995).
The final step in the identification of a diseasegene after candidate genes have been
identified is the search for a mutation within one of these gen es. The occurrenc e of this
mutation in all the affected individual s and none of the unaffected indi viduals is evidence
that the part icular gene causes the disease. However, before a gene is considered to be the
true cause of a disease it must first be tested in other families with the same disease . This
is done in case the mutation in the cand idate was a coincidence and not the actual cause of
the disease. Once this bas been determ ined it is then necessary to test other families withthe
same disease for similar or novel mutations in the gene. The most accurat e method of
finding genetic mutations is direct sequenc ing. However, there are other techniques such as
denaturing gels or singl e stranded conformational polymorphism analysis which can give
consistently reliable results (Orita et al., 1989). Once the gene is identified, a search for the
exact function of the gene product begins in hope that a way to supplement its function will
be available (Papadopo ulos, 1995).
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1.3 CLINICAL PRESENTATION OF THE FAMILY
1.3.1 Geneology
AlargemultiplexNewfoundland familyof 153individuals (U I) wasidentifiedwith
sixchildren ( PIO 49, 50, 51, 53, 54 and 55) in three interrelated sibships A, BandC affected
with a renalcystic-biliary disease complex (Fig. 2). The parents of the affected individuals
in sibship A are 3nl cousins, sharing their maternal great-great-grandparents (PlOt 52 and
153). In sibship C the parents of the affected individual (pIO 55) are relatedas 2oc1 cousins,
sharing paternalgreat-grandparents (PID 150and 15I). The parents of individualsinsibship
B are related to beth sibships A and C. The father of sibship C(pID 40) is the2nd cousinto
the father of sibsip A (PID 29) and the motberof sibship B (pID 41) is the lSi cousin to the
father of sibship C(pID 38). Clinical data were collected by Dr. Patrick Parfrey, Patient
Research Centre. Health Sciences Centre, St. John's, Canada, and Dr. Benvon Cramer,
Janeway Child Health Centre, St. John's, Canada. The clinical data were reviewed by Dr.
Lisa Guay-Wcodford, University of Alabama,Birmingham, USA.
1.3.2 Sibship A
The proband(PID 49), a male, presentedat 2 years of age with failure to thrive and
hepatosplenomegaly. Liverultrasoundshowed an abnormal parenchymaandcysts. At age
5 he had portalhypertension andvaricies in additionto congenital hepatic fibrosis identified
througha liver biopsy. Kidney ultrasoundat age 8 indicated a non-functioningleftkidney.
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Theright kidneywashypertropiedwith cysticchangesanda mild increase inechogenicity
af therightk idneywiththepreservationofcorticomedullarydifferentiation. Thisindividual
requiredasplenorenal shunt at age 13 and starteddialysis soon after. A kidney transplant
was performedat age 14 whichis still functioning at age24. IndividualPIDSO. female,
presentedwith an enlargedliverand spleenat age 1. l iver ultrasound showed increased
ecbogeniciryand an abnormalparenchyma. A liver biopsy, performedat age 8, revealed
extensive portal tract fibrosis with bile duct proliferation indicating congenital hepatic
fibrosis. Echcgenicity in Teft kidney increased in cortex but the right kidney remained
normal. A kidney ultrasound,age 16, revealed normal corticomedullarydifferentiation.
howevershedid requireda splenorenalshunt Serumcreatinine was S3umol/l, at age 17.
Individual PID 51, female. presented with an enlarged liver at age 2. At age S. liver
ultrasound revealed cysts in right lobe with diffuse increase in size and increased
echcgenicityand enlargedspleenwithumbilical veinvarices. Kidneyultrasoundindicated
amildincreaseincorticalecbogenicitywith nonnalcorticomedullerydifferentiationwithout
cysts. Atage 10.serumcreatininelevelwas57)JmollL.
I.J .J Sib,bi p B
The affected female (PlD 53) presented a' age 6 with symptoms of
hepatosplenomegaly andcongenital hepatic fibrosis wasdiagnosedin a liver biopsy. Liver
ultrasound showedincreasedechogenicitywhilerenal ultrasoundrevealedlarge,speckled,
ecbodensekidneyswith a lossofcorticomedullary differentiation but no discretecysts. At
Figure 2· Extended pedigree of the UI Newfoundland familyaffected with PKD .

Figure 2 Pedigree.
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age 16, serum creatinine level was 125 pmol/L. At age 22, she had asymptomatic portal
hypertensionand serumcreatinine was217umol/L, indicating decreasedkidney function.
The affectedmale (PID 54) presentedwith hepatosplenomegaly at age 8. Liver ultrasound
showed increased echogenicity with no discrete cysts. Biopsy revealed bile duet
proliferation with minor fibrosis. Renal ultrasonography displayedlargespeckled ecbodense
kidneys with a loss of corticomedullarydifferentiation, and no cysts. At the age of 15 yean
he had a splenorenal shunt and a year later be bad a kidney transplant which continues to
functionat age 21.
1.3.4 Sibsbip C
The single affected individual in sibship C (p1O55) had hernia repair at age2 and
abdominal ultrasound. Multiple large cortical and medullary cysts wereobserved on his
kidneys, consistent with ADPKD. with the preservation of the renal architecture. Liver
ultrasound was normal. At age 7, serumcreatininewas68 umcl/L. Asof yetthis individual
has not displayed any liver or spleen dysfunction (Table 1).
1.35 Suitability for genetic study
This family is ideal for a geneticstudydue to several factors relating to the pedigree
structure. First, the pedigreecan be traced back sixgenerations giving a goodrecord of the
familyhistory. Second, the family is fairly large andbasseveral affected individualsin three
differentsibships allowing for comparisonof several affectedindividuals. Third, within the
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~ Summaryof manifestationsobserved intheaffectedindividuals ineachof me three
sibshipsof tbe Ul family.
Sibship Kidney Liver Spleen Esophageal
involvement involvement involvement varicies
A V V V V
B V V V
C V
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family as a whole, there are two consanguineous marriages making it very likely tbat the
affected individuals are HBDinthediseasearea (Landerand Botstein, 1987; Sheffield et aI.,
(998).
1.4 POSSIBLE DI SORDERS
1.4.1 Disease Considerations
The family pedigree did reveal useful infonnation when considering possible
diseases. It is clearfrom Fig. 1that there isno biastowardsmalesor femalesandis therefore
not linked to theX chromosome. There is no evidencethatmaternal or paternalinheritance
plays a role which rules out the involvement of mitochondrial DNA or the Y chromosome.
The observation that the disease only appears in one generation and there are two
consanguineous marriages led to the conclusionthat it is of an autosomal recessive nature.
The pathological features included enlargedspleen, enlarged polycystic kidneyswitha lack
of corticmedullarydifferentiation, enlarged cystic liverand high serum creatinine levels all
of whicb occur within the first few years of life. Two human polycystic kidney diseases
matcb this profile; autosomal recessive polycystic kidneydisease (ARPKD) and juvenile
nephronophthisis (NPH) both ofw hicbare known to be caused by autosomal genes andare
recessive in nature. Another human disease which closelyfollows the list ofpb enotypic
features found here is autosomal dominant polycystic kidney disease (ADPKD). While
ADPKDis not a recessivedisease, the features closely match the list of phenotypes found
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in the VI family. Finally, research in polycystic kidney disease has focused on similar
diseases inmice inanattempt to find humanbomologs. The mouse mutationsbpk andjcpk
havebeen found tocause polycystickidneys withdifferentseveritiesandhaverecently been
found to beallelic (Guay-Woodford et al., 1996). This finding wasquite intriguing as the
mutationsare foundin anareaof the mouse genomeknown to besyntenic topartofhuman
chro mosome 10.
1.4.2 Juvenile Nephronephtb tsls
Juvenile Nephronophthisis(}o'PH)(MIM# 256100)wasfirstreported inthe literature
in 1945 by Smith andGraham; however, the first description is attributed toFanconi et al.
in 1952 (Gusmanoet aI., 1998). NPH is characterized by its recessive inheritance andthe
formationofcystsatthecorticomedullaryjunction, chronictubulcinterstitialnephritis. Itwas
later discovered thatNPH is alsoassociated with congenital hepatic fibrosis (Proesmans et
aI., 1975; Witzlebenand Sharp, 1982). In most cases, children initially presentat aroundage
4 years with polyurea, polydipsia and isosthenuria due to a reduction in the ability of the
kidney to concentrate urine (Konrad et a!., 1998; Gusmano et at . 1998). NPH symptoms
include: slowly progressing renal failure with shrunken kidneys and diffuse interstitial
lesions. of t·1 5nun in diameter, eventually leading to end stage renal disease (ESRD) at
median age of 13 years (Haider et al., 1998; Fick and Gabow, 1994). Ultrasonography
reveals medullary cysts and a loss of corticomedulJary differentiation in kidneys.
Histological analysis reveals athickening in the basement membranes. Analysis usinganti-
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basement membrane antibodies against proteins such as laminin and type rv collagen
antibodyrevealseithernormal ora completelackof binding(Konradet aI., 1998; Gusmaeo
et a1.• 1998). NPH is estimated to be the cause of 10 - 14% of all renal failure in children
(Gusmano er al., 1998). Although purely renal. !\"PH can be associated with nonreral
diseases as in Senior-Leken disorder (MIM ;; 266900), nephronophthisis and retinal
dystrophy. Boneabnormalities have also been reported to be associated with KPH, some of
these include: cone shaped epiphyses, and iliac and acetabular malformations (Gusmano et
aI., 1998; Konrad er aI., 1998).
In 1993 one of the genes causing ~'PH (!'."PH-I) was localized to a region on
chromosome2q12-qJ3(Antignac et al., 1993). ~"'PH ·l bas since been cloned and identified
as a novel gene (Hildebrandt, 1998). In 1998 the NPH·2 locus was discovered through
homozygosity mappingusing a large multiplex Bedouin family whose affected members
displayedtheNl'H phenotype butdidnotmap to thel\"PH-I locuson chromosome2(Haider
et al., 19987). Thel\rpH-21ocusmaps to a 12.9cM regionon chromosome9q22-31, Flanked
by the markers D9S280 and GGAT3G09.
1.4.3 Autosomal Dominant Polycystic Kidney Disease
ADPKD(MIM # 600666) is present throughout the world and its prevalence is
estimatedto be approximately 1:200-1:1000 (Bycroft et al., 1999; Catvet, 1998; Merta et
al., 1997). There areat least threeknownloci responsible for ADPKDon chromosomes16p
13.3 (known as the PKDI locus), chromosome 4q13-q23 (PKD2 locus) and at least one
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other, as yet unknown. locus. The disease can be quite variable depending on which gene
is involved. resulting in ESRD at significantly different times in life. However, even
individuals in the same family can display remarkable variability in the severity or age of
onset of the disease, including presentation as congenital polycystic kidney disease and
hepatic fibrosis {Chauveauet al., 1997). Novel mutations of ADPKD have been identified
(Kim" aI., 2000; Iglesias et aI., 2000).
1.4.4 ~!ouse bpklj cpk mutations
Themutationsbpk/jcpkareactuallygenetic mutationswhichoccurin themouse and
give a phenotype which mimics several human PKD mutations including autosomal
recessivepolycystic kidneydisease(ARPKD). The bpkmutation is a less severefonn oftbe
disease and arosespontaneously in an inbred population of laboratory mice and thus most
likely representsa point mutation, whereas thejcpk mutation was induced by the mutagen
chlorambucil which is known to cause deletions and rearrangements in genetic material
(Iakoubova et al., 1994; Brydaet aI., 1996; Mcyer et at , 1994). It was found that these two
mutations, which producedifferentphenotypes, occur within the same discrete intervalof
the mouse genomeandit is now thought that they are al1elic (Guay-Woodford eraI., 1996).
The locus of the mouse genome where this occurs is syntenic to a 17 cM region on human
chromosome 10. The notion that differences in the severity of ARPKD could be due to
allelic differences is intriguing.
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1.4.5 Autosomal Recessive Polycystic Kidney Disease
ARPKD(MIM# 263200) isoneof the most common hereditaryrenalcysticdiseases
in children, involving the kidneys and the biliarytract. As many as 50% of children born
with ARPKD die within hours of birth due to respiratory failure. The principal
manifestations cf the disease involve dilation of the collecting ducts and dysgenesis of tbe
portal triad. Affected fetuses typically display bilaterally enlarged kidneys and
oligohydramnios. As a result of the oligohydramnios, fetuses often display the "Potter
phenotype" consisting of pulmonary hypoplasia,a characteristic facies, and deformitiesof
the spine and limb (Fig. 31, b, c and d). Children who survive the neonatal period often die
from hypertension, renal failureand portal hypertension due to hepatic fibrosis. It is now
known that not all affected individuals die postnatally, but that there is a widespectrum of
phenotypes, including a varied survival rate. However, with increased age there is an
increase in life-threatening renal failure (Zerreset aI.,1984; Gang and Herrin, 1986; Deget
et at , 1995) The frequency of this disease in the general population is estimated to be I to
2 for every 10,000 live births (Zeres et al., 1988; Zerres et al., 1996; Zerres et al., 1998;
Guay-Woodford et aI., 1995). Until quite recently, it was thought that there was only one
gene for this disease, PKHD-l, located on chromosome 6p21.1-12 (Fig. 3e). However,
recent research bas foundevidence to refute this belief. Zerreset al. (1999)have found two
siblings suspected to be affected with ARPKD but who do not map to the chromosome6
region. This was the first time that ARPKD-like symptoms did not map to 6p21.1-12
although the phenotype of the affected individuals is described as being similar to six
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previously described sibpairs(Gillessen-Kaesbach et al., 1993) It is not yet known where
the suspected new genemaps.
Acommon feature intbedevelopmentofARPKD is tbethickeningof thecollecting
tubulescausedby localizedproliferationandsecretionbyepithelial cells whichde\'e1opinto
fluid filledcysts. These cystscontain biologically active proteins for epidermal growth
factor receptor (EGF· R) (Ganone et aI., 1990; Avner, 1995). In addition to the
mislocalization of EFG-R. it hasalso been shewnthatthere is an increase in the mRNA.
protein andtyrosine kinase activityof EGF·R (Avner andSweeney. 1995; Wilson eraI.,
1993; Orellana el al.,I995). Recently, by decreasing the tyrosine kinaseactivity in mice
programmedtodevelopARPKD,Richardset al.(1998)wereableto showthatit isthe EFG·
Rtyrosinekinaseactivitywhicbcausesincreasedcellproliferationleading tocystfonnation.
I. was also found thatTransformingGrowth F3C1or (TGF}-aincreasedthe tyrosine kinase
activityofEGF·R andleads to larger cystic lesions.This evidence pointsto the EGf-TGF·
a -EGF-R loopas a mediatorof theproliferative expansionof collectingtubuJe epithelium
in ARPKD(Sweeneyand Avner, 1998).
1.5 PREVIO US STuDIES ON THE NE WFOUNDLAND FAMILY
Previous study of this family involvedmicrosarelliteanalysis of the NPH·I region
of chromosome 2 and the ARPKD region of chromosome 6. It was determined that
polycystic lcidney disease in this family did notmap to the NPH-I locus but that insibships
A andB it did maptotheARPKDcritical region of chromosome6. Therewasno
Figure 3: Newborn with massively enlarged polycystic kidneys (a) representing severe
ARPKD. Cutsection reveals multiplecystsgivingthe kidney a spongy appearance
(b) (Zerres et at. 1994). c) Polycystic kidoey with uniformly distributed cysts.
Note the lack: of corticomedullary differentiation. d) Photograph of a newborn
displaying the common facial features of Potter phenotype. Note the prominent
infraorbitalfolds. e) Ideogramofchromosome 6 depicting the markers around the
ARPKDregion.
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homozygosityfound in theaffectedindividual in sibship C (results reported in detail below)
(Jones, 1997).
As there was no of evidence for ARPKDin sibship C, it was decided that additional
diseases at other loci should be ruledout before ARPKDcould be inferred as the disease
affectingthe individuals in sibships A and B.
1.6 OBJ ECTIVES OF STUDY
The objectives of this study were to;
i) investigate the possibilityof a genetic disorder other than ARPKDin the
UI family.
Ii) produce a Phage Artificial Chromosome (pAC) contiguous map of me
ARPKD criticalregion.
iii) find new microsatellite markersin order to narrow tbe critical region
further.
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2. MATERIALS AND METHODS
2.1 PREPARISG DNA FRO" WHOLE BLOOD
Blood was collected in EDTA rubes (volumes are given for 5-7mL of blood).
Approximately 45mL of warm (l7 'C) NH,CI:Tris solution (900mL of 0.155M NH.C1;
100mLof 0.17 M Tris-HCI, pH 7.65)wasadded to 5mL of blood in 50mL centrifuge tube
and incubated at 37"C for 5 minutes before centrifuging at 2500 rpm (1000 x g) for 5
minutes. Thesupernatant was poured off, IOmL saline (0.85%KaCI) was addedand the
tubewasvortexedandcentrifuged again.Thesupernatantwaspoured offand3mLofnuclei
lysis buffer(10 mMTris-HCI, 400 mMNaCl, 2 mMEDTA, pH 8) was added to the cell
pelletwhichwas vcrtexed and transferred to ISmL centrifuge tube. Then O.2mLof 10%
50S andO.5mL of PronaseEsolution (l mglmLin 1%50S, 2 mM EOTA)was addedand
thetubewasincubated at37"C overnight (or2 hours at 5511Q.
ImL of saturated NaCI wasaddedand the solution was shaken vigorouslyfor 15
secondsandcentrifuged. at2500rpm(1000xg) for15min. The supernatant waspouredinto
a lSrnLrube whichwasfilledwith95%ethanol. The tubes wereinverted severaltimes to
precipitateoutthe DNA. The DNA clump wasfishedout witha with a 9"glass book. (9"
Pasteurpipette; tip meltedto forma hook) andwashedseveralrimes witha streamof 70010
ethanolandallowed10 airdry beforebeingdissolvedinl oo-5oomLTE(10 mMTRlS-HCI,
I mMEDTA.pH8) overnight bycracking off tip of book intubeandgently mixingon a
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rotator for anhourbeforequantifyingusingUV spectrometry. DNAsampleswerestored
at 4'C (Based on Miller et aI., 1988).
2.2 IDENTIFI CATIO N OF DISEASE LOCI
2.2.1 Screening with I\1icrosatellites
Oligonucleotide primers fromthecritical regions ofN PH- l (Medhioubetal., 1994),
NPH-2 (Haider et al., 1998), mouse bpkljcpk (Lisa Guay-Woodford personal
communication), and ARPKD (Jones, 1997; Mucher et aI., 1998) (Appendix 1) were
obtainedfrom ResearchGenetics (Huntsville, At) andlabeledwith" P(Mix: 1.08j.1L 20JlM
forward primer, 0.45/lL OnePborAlI buffer (Amersbam, Bridgewater, NJ), 2.70jJL 6000
Cilmmo l y-" P-ATP (Amersham) and O.30~L T, PNK (Amersham) (total of 4.5~L) . Vortex
and pulse in acentrifuge then let sit in37°Cwaterbath forat least 30 min(place in freezer
if notusing immediately). Add 1J.1L III0 DNAsamplesto separatesmall polymerase chain
reaction (PCR) tubes . To each tube add 9~L of PCRcocktai l (244.88,"L dH,o, 42 .2~L lOx
Tfl buffer, 5.3~L 25 mM MgSO" 67.5~L 1.25 mM dNTPs (6.25,"L each of 100mM A, C,
G and T stock (Amersham) in 475,"L dH,o in a 2mL tube)., 8.78~L each of20~M forward
and 20llM reverseprimers, 3.38JlL 5u/IlLTfl polymerase (promega, Madison,WI) , 4.51lL
radiolabeledprimers). The sampleswerethenplaced inaPerkinElmer9600thermal cycler
anddenaturedby hearing to 95°Cfor5 minutes, cycled35times using; 95°Cfor45 seconds,
45°C· 60°C for 30 seconds, 72°C for 35 seconds, then72°C for 5 minutes and finally
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incubatedat 4°C until ready to use. 2.5JlL of "DNA Stop" solution" (0.05% bromophenol
blue and 0.05% xylene cyanol, 9.5mL fonnamide and 400llL O.SM EOTA) was added to the
samples and2.5IlL was then run on a 6% polyacrylamide gel (ISJlL TEMED (Sigma, St
Louis, MO), 6mL l OxTBE (108g Trizrnabase (Sigma), 55g Boric acid (Sigma)and 40mL
O.5M EDTA (BDH Inc, Toronto, 0),1 in IL dH,O), 9mL 40% Acrylamide (dissolve 95g
Acrylamide(Bio Rad)and5g Bis-Acrylamide (Sigma» in 250mLand filter with Whatman
#4, IOmL dH,o , 20g Urea (Sigma), 19mL Formamide (BDH Inc). 480flL 10%
Ammoniumpersulfate (promega) at 40W constant power. Once the gel had run an
appropriateamount of time the electrophoresis was slopped and the gel was transferredto
3mm Whatmanpaper by drying on a gel drier (Bio Rad, model 583) for approximately 1 V:
hours. Autoradiography was then performedby placing the gel in an X-raycassette with a
DuPont (Mississauga, Ontario)Lightning amplifyingscreen and Xcray film (AGFA Curix,
Toronto, ON)and placedina dark-room for I M 10 days before being developed. Genotyping
was performed more than one time when necessary.
2.2.2 Haplotype Analysis
Marker alleles werescored fromautoradiograpbsat least two times by two different
individuals ina blinded fashion. Haplctypes were constructed manually for the family for
each of the candidate loci using all available microsatellitedata in such a way that they
represent the minimal number of recombination events. Sharing of haplotypes between
affected andunaffected individuals within the family was used to excludea locus. Support
·28·
for linkage to a locus was established if the affected individuals in the V I family displayed
HBDin the critical region andtheirunaffectedsiblingsdid not(LanderandBotstein, 1997)
or if'affected individual s shared one copy ofa suspected mutated locus from one paren t and
the same cbromosomauocus fromtheotherparent. This would reveal the possibility of two
separate muta tions.
2.2.3 Linkage Analysis
Linkage analysiswascarriedout inordertosupport tbe resultsofhaplotype analysis.
Two-point linkage analysis was carried out using the MLINKsubroutine of FASTLINK
(v4.0P) (Lathrop and Lalouel, 1984; Cottingham et al., 1993; Scha ffer et al., 1994). In the
caseofmouse bpkljcpk, humanstudies hadnotpreviouslybeenperformedso fullpenetrance
was assumed. The other diseases were mode led as being recessive with a penetranc e of 1
(Haider et aI., 1998; Antignac et al., 1993; Zerres et aI, 1994). Two point LOD scores were
calculated for all micr osatellite markers sp anning the critical region of each locus .
Significantly negative LOD scores (:~ ~2.0, a = 0) were used as criteria for exclusio n of
linkage to a disease gene while positive LOD scores were taken as support for linkage.
2.3 OBTAI NI NG PA C C LONES
2.3.1 The PAC Libraries
A human PAC screening library was obtained from Genome System s Inc. (S1.Louis,
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MO) The humanPAC library is housedin 321 microtiterdishes, each with384 wellswith
onePAC/well. DNA is combined fromblocksof 10dishes for a totalof3 2 "Upperpools"
(i.e., Upper pool #1 has DNAfromdishes 1-10). The DNA from each microtiterdish is
pooled individually to create 321 "Plate Pools", Once the "Upper Pools" have been
identified, a screen of the appropriate platepoolswill reveal the plateon whicha PACof
interest is located. To create the"Downto thewell" pools, DNA fromeachcolumnandeach
rowis pooled tben DNA from 10columnandrow pools arecombined (Fig. 4).
A peR is performedfor 3Scycles using oligos from the ARPKD region to obtain
clones which are able to hybridize to complementary sequences within the region and
amplifyanSTS. The productsaf the reactionswere runon a 2% agrose gel. Cloneswhich
contained a sequence complementaryto theoligos will displaya band identical insizeto a
positive control. By usingthis methodit waspossible to narrowPACclones to a specific
dish, column. and row. Once PACs wereidentified they weresubject to Pe R usingother
markerswithin the region in order to determinewhicb marker sequences theycontained.
2.3.2 Isolating PAC DNA
PAC clone agar stabs wereorderedfromGenomeSystemsInc.. Bacteriafromthe
stabs were streaked on 2S~glmL LB-kanamycin (LB-kan) plates and incubated at 37"C
overnight The next day a single colony was pickedand transferredto a 25mL flask
containing 3mL 2S~glmL LB-kan andincubatedat 37"Covemigbtwith 2SOtpm shaking.
Thenext morning2mL of the overnightculturewasusedto innoculateSOOmL of2Sj.1g1mL
~ a) Illustration depicting bow the PAC"Upper Pools" are created. The picture
indicates that there are32upperpoolsamples,eachcontainingthe DNAof t0plates
which is equal to 3g4OPAC clones. b) Illustration depicting bow the PAC "Plate
Poots" arecreated. The DNA from the384 PACson eachdish arecombined to
createonesample. c) Illustrationdepictingbowthe PAC "Down to the Well" pooh
arecreated. Each colwnnandeachrowof a group of 10 platesarecombinedinto
onesample.
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LB-kanina 2Lflask. Theculture wasincubatedat37"Cwith250rpm shakingforI Y2 hours.
The culture wasthen induced withIPTGtoa finalconcentrationof O.5mMandincubated.
as above, fora further5 hours. Theculture was thencentrifuged ina 250mLpolypropylene
bottleatSOOOxg for 10min. andthesupernatant was poured off. At this pointthebacteria
may or maynothave beenstored overnightat_lOce andthawed on icewhen needed. The
cell pellet was resuspended in 20rnL PI buffer (50mM Tris-CI, pH 8.0, IOmM EOTA,
100~g/rnL RNase AI) and lysed by adding 10rnL P2 buffer (lOOmM NaOH, 1% SOS
(Sigma, St. Louis, MO) madefresh daily) and incubatedat room temperature fornomore
than 5 min. The lipids, proteins and 5DS were then precipitated by adding 20mL
neutralizationbufferP3(3.0MKAe,pHS.S, storedat4°C)andincubating onicefor15min.
Thecellularmaterial wasthentransferredto N 'O48mLpolypropylene tubes andcentrifuged
at 10000rpmfor30 min. The supernatant wasrecentrifuged, if needed, andtransferred to
a fresh 50mLtube. A Qiagen (Valencia, California) tip500 was equilibrated with IOmL
QBT buffer(750nMNaCI, 50mMMOPS(Sigma), pH 7.0, 15%isopropanol, 0.15%Triton-
X (Beckman Instruments,Fullerton, California) andallowedto runthroughbefore the cell
supernatant wasaddedtothetip 500. Onceall thecell lysatebadnul through, the tipwas
washedwith30rnLbuffer A (0.75MNaCI,50mMMOPS, pH 7.5, 15% ethanol) andeluted
intoa 48mLpolypropylenetube using two5mLaliquots of buffer B (lAM NaCI,50mM
Tris-HCI, 15% ethanol, pH 8.1-8.2) heated to 65°C (Appendix 2). The DNA wasthen
precipitated and resuspended in 500~L TE buffer (10mMTris-HCI, ImM EOTA, pH8.0).
The DNA was quantified using a fluorimeter and stored at 4°C. The method usually
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produced a yield of30-60~g of PAC DNA.
2.4 PRECIPITATING AND QUANTIFYING DNA
In order to sequence the endsofth e PAC clones it was necessary to first determine
the mass of ONA obtained and precipitate a specific a liquo t. DNA was quantifi ed using a
DNA fluorometer TKO 100 (Hoefer Scientific Instruments, San Francisco). 2mL
fluorometer buffer (!Oml 1NE (I OOml 1M Tn "HCI (pH 7.4), I OOmL 0.1M EDTA, 58.4g
NaCi in lOOOmL dH,o), 90mL dH,o, IO~L Im g/mL Hoechst dye) was placed into a
cuvette. the "scale" knob was turned all the way to the righ t and the machine was zeroed
using tbe "zero" knob. 4mL of250 JlglmL calf thymus DNA was added to the cuvette and
mixed gently and the scale knob wasadjusted to obtain a reading of 500. The cuvettewas
pouredout and rinsedwith ImLbuffer beforeadding2mLbuffer which wasused to rezero
the machine. 5mL of sample DNA was added to tbe cuvette, mixed, placed in the
fluorometer and the scale reading was taken. The concentration of DNA in the undiluted
sample was taken to be 2 X scale reading/5 (~g/mL).
DNAwas precipitated by adding 10% 2M NaAc (pH 3) and two volumes of -20"C
95%ethanol and mixing. The mixture wasthenplacedat_20oeovernightor at _70oe for 15-
20minutes andspun in a microfugefor 20 minutes. The supernatant was poured offandthe
samplewaswashed with70%ethanol andspunfor 10minutes. The ethanol was wicked off
and the DNA peIlet was dried under vacuum at room temperature.
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2.5 PRODUCING NON-eO~I~IERCIALLY AVAILABLE OLIGONUCLEOTIDE
PRJ~IERS
Primers for which the sequence was known but which were not commercially
availabledue to lowheterozygosity or becausethey were newly discovered were inputted
into the Cortec primer design automated order form (hnp:/I'Ao"\1ow.cortec.queensu.ca/). The
web based""primer3"(bttp:l/v."\\ow.genome.\\i.mited ulcgi-binfprimer/primer3_www.cgi) was
used to design novel primers from newly discovered DNA sequences. This program
automatically designed primers around a specifiedsequence, automatically picking cligos
withoptimal traits. Theseprimersequenceswerethen inputted intotheCorteeprimerdesign
page. All primers were synthesized on a scaleofO.2~mole and were TLC purified.
2,6 SUBCLONING PAC CLONES
In order to screen the PAC clones for novel microsatellite repeats it was necessary
to cut the DNA into smaller pieces, ligate it into a suitable vector and transform it into a
suitable bost bacterial cell [0 be screenedfor repeat DNA.
2.6.1 DNA Preparation
16j.1g ofpU CI8 DNA (a kind gift from DonnaJackman who was working in Dr.
David Heeley's lab) was digestedwitb 2~L (20,OOOu!mL) BamHI(New England Biclabs,
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Beverly, MA)using2xOnePhorAIIbuffer(Amersham)anddH20 in40""L total volwneand
incubated in a 3JOe water bath overnight The enzyme was deactivated by placing the
reaction in a 650(:water bath for 15 minutes. Digested IOllgof PAC DNA with 1.5JlL
(6OOOuImL) Sau3A (Arnersbam) using l x OnePborAIi buffer (Arnersham) and dH,O in
SOJ.1 L total volume and incubated in a 3JOC water bath overnight, The enzyme was
deactivated by placing the reaction in a 65°C water bath for IS minutes. To assess the
digestion, 4j.1g af the digested pUCIS and SJlg af the digested PAC DNA were run a on a
1% agrosegel beside a A-HindIllmarker (Amersbam).
I~L (I u1~L) Shrimp Alkaline Phosphatase (SAP) (United Sta tes Biochemica l
Corporation, Cleveland, OH)wasadded to theremaining 30""L pUCIScocktail alongwi th
3.SJ.tL lOxSAP buffer. The mixturewas incubated in a 3rC water bath for 1 hour. The
enzyme wasdeactivated by placing the reaction in a 65°Cwater bath for 15 min.
In order to minimize i.!le amountof bacterialchromosomalDNA present in the PAC
DNA, each of the isolated PAC samples were treated with 15u of lOu1~L Plasmid Safe
adenosine triphosphate (ATP).Dependent DNase (Epicentre Technologies, Madison, WI)
and ATP (EpicentreTechnologies) to a final concentration of ImM. The reactions were
placed ina 3rC waterbathandafterone hour, ATPwasagainaddedtoa finalconcentration
of2mM and the reactionwasallowedtocontinueovernight. The DSA was reisolated from
the reaction by performing a 1:1 Phenol (Fisher Scientific, Fair La"'11. NJ}Chloroform
(FisherScientific)extractionfollowedby aChloroformextractionalone. TheDNAwasthen
precipitated and washed several times with 70% ethanol. The DNA samples were
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resuspended to a final concentrationof O.l llg/J,lL.
2.6.2 DNA Ligation
I ~L (O .3 53~g) pUCl 8 (digested and treated with phosphatase) was combined with
O.56~L (O.106~g) digested PAC DNA, lflL ligation huffer (660~L1M Tris , 66flL 1M
MgCI" lOO~L 1M DDT, 50~L 100mM ATP and 1 24~L dH,o split into 50flL aliquots and
stored at-20 °C), lllL T4 DNA ligase (MBI Fermentas, Elambcrough , Ol\')and 6.44IlLdH20,
for a total reactionvolumeof IDilL. A pUC18 negative control (1J.1L pUC18, IJ-LL Ligation
buffer, IIlL T4 DNA ligase, 71ll dH20) was also set up for comparison. The ligation
reactions were allowed to incubate at room temperature overnight.
2.6.3 Prepa ring Competent cells
E. coli DH2 cells were grown at 37°C overnight in 3mLof LS broth and O.5mL of
that culturewas usedto innoculate 500mL LB broth the next day. The cells were grown at
37°Cuntiltheculture reached an optical density of 0.800 ~ 1.000. The cells were centrifuged
in a polypropylene bottle at 4000 rpm for 10 minutes and thesupernatant was pouredoff.
The cellswere resuspended in 250mL O.IM CaCI2 and incubated on ice for 30 minutes. The
cells were recentrifuged and resuspended in 5mL cold O.I MCaCl2 + 150/0 glycerol and split
into 50~L aliquots and frozen at _70°C until ready for use.
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2.6.4 CeU Transform ation
A 50~L aliquot of compe tent E. coli DH2 cells was thawed on ice and 450~L cold
0.1M CaCl2 was added. In a 1.5mL tube, 80~L E. coli DH2 cell suspension was added to
theIO!J.L ligation reactionand incubatedat roomtemperature for 30 min. The cellswereheat
shocked by placing them in a 42QC water bath for no morethan 45 seconds. ImL LB was
added and placed in a 3rC water bath for 40 minutes. Cells were then centrifuged cells in
a microfu ge for I minute, the supern atant was poured off and the rube was gently rapped to
resuspend the cells in the leftover supernatant. Each suspension was divided in half and
spread on 50 ug/ml, LB-Carbenicillin (LB-carb) plates and placed in a 37"C incubator
overnight.
2.7 SCREENING FOR NOVEL MICROSATELLITES
2.7.1 Transfe r ring Colon ies arid Fixi ng DNA
Colonies were picked and transferred, in duplicate, to gridded Lg -varb plates which
were incubated at 3rc overnight The colonies were transferred to nitrocellulose paper
(Gelman Science, Ann Arbor, MI), placed in a glass dish, colony side up . containing filter
paper soaked with 10% SDS and incubated for 3 minutes. The nitroce llulose was then
placed in a second dish containing filter paper soaked in denaturing buffer (0.5M NaOH,
1.5M NaCI) and incubated for 5 minutes. The nitrocellulose was then placed in a third dish
containing filter paper soaked in neutra lization buffer (1.5M NaCI, O.5M Tris·H Cl pH 8.0)
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and incubated for 5 minutes. Finally the nitrocellulose was transferred to a fourth dish
conuining filter paper soaked with 2x SSPE buffer (2Ox SSPE; 3.6M NaCl, 200mM
NaH2PO..and 20mMEDTApH 7.4) where thecell debriswasrubbedoffwi tha tissue. The
nitrocellulose was incubated in that solution for 5 minutes before being rinsed in 2x SSPE
and place on filter paperand allowedto dry overnight at roomtemperature.
2.7.2 Probing Colonies for STRPs
Nitrocellulose membranes were placed in glass hybridizaton rubes with 15mL of
prehybridization solution (2SmL 20x SSP£, 1000SOx Denhardt' s solution (Sg ficol, Sg
polyvinylpyrrolidone, Sg bovine serumalbumin) 0.1%50 5 inSOOmL, filtered and storedat
-20"C), and rotated ina hybridizationoven (Robbins Scientific, model400), set at 50°C. for
2 hours. Three oligos, (Gn lll>(CT) IOand(CAG )s. wereradiolabeled with 32p by combining
I.S~L of eacb lO~M oligo, 4.5~L 6000 CUmmoly."P.ATP, I ~L lOx T, polynucleotide
kinase(PNK) buffer, lul, T..PNKand incubating at 37"Cfor30 minutes. Once the 2 hour
incubation wascompletetheprehybridizationsolutionwasremoved and replaced with fresh
prehybridizarion solution containing SJlLof each of the three oligos and rotated in the
hybridizationoven overnight
The next day the membraneswereremoved fromthe hybridization rubes and washed
three times in200mLof fresh2x SSPEina glassdishwithgentle shaking for one houreach
wash. The membranes were thenallowedtoair dry andplacedin an X-ray cassette withX-
ray film for threenightswitha Lightning-Plusamplifying screen (DuPont Cronex), at ~7CfC
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before developing.
2.8 SOUTHERN BLOTTING
In order to confirm that the suspectedsubclones did actually contain microsatellite
DNA, the individualsubclonesweregrownup in order to obtaina large quantityof subclone
DNA.The PACfragment insertwasthendigested, runon agel, southernblotted,andprobed
to determine if the oligo properly hybridized to a repeat sequencewithin the PACsubclone
fragment.
2.8.1 Isolating subclcned DNA
Bacteriacontainingsubclones suspectedofhavingmicrosatellite repeatsweregrown
overnight in 3mLofL Bbrothina 25mLflaskat37°C. Thebacteriawerethen isolated using
the Wizard miniprep (promega) system according to the manufacturer's protocol and
resuspended in 50JlL TE buffer.
2.8.2 Analyzing Subclcn es
Once isolated, theDNAinsertwascutout ofthe pUCI8 vectorbydigesting theDNA
sample in the following reaction; lJlL 20.000ulmLBcoRI (Amersbam), IJlL 18.000uJmL
HindIll (Amersham), 8~L DNA, 4~L OnePhorAII buffer (Amersham), 6~L dH,o. The
reaction wasplaced ina 37"Cwater bathovernightbefore beingrunona 1% agrose (Sigma)
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gel for 3 hours.
2.8.3 Transfer ring DNA
Once properly photographed, the gel was placed in a glass dish containing 500mL
denaturingsolution (O.6M NaCl, OAM NaOH)withgentleagitation for 20 minutes at room
temperature. Thesolution waschangedand the incubationwasrepeatedoncemore. The gel
was thenincubated in SOOmL neutralizingbuffer(1.5MNaCl, O.5MTris·HCI, pH 7.5)for
20 minutes. Again, this was done withgentle agitation atroomtemperatureandrepeatedone
time. The gel was then placed in lOx sse (20x sse: 3M NaCI, a.3MSodium Citrate
[Trisodium Salt Dihydrate]) at room temperature with gent le agitation for 15 minutes. A
GeneScreenPlus hybridization membrane(NENLife Science Products,Boston, MA), was
cut to the size oftbe gel and placed in water to wet and then into a lOx solution ofSSC for
15 minutes. A glass plate was placed over a glass dish containing 200mi lOx SSC anda
piece of 3mm chromatography paper (Wbatman, Clifton,NJ) was used as a wick by cutting
it to thewidth of the gel and placing it over the plate witheach end in the lOx SSC. The gel
was placedon top of the wick and Parafilm (AmericanNational Can., Menasha, WI) was
placedover any partof the wick that the gel did not cover. On top of the gel was placedthe
transfermembrane and a piece of3mm Wbatman paper (cut to size). On top of this was
placeda stack of paper towels approximately six to eight inches thick, and a glass dish for
weight. The DNA was then allowed to transfer for 16 to 24 hours.
2.8.4 Probiog (or STRPs
The Southern blot membrane was probed in the same manner as the bacterial
subclone colonies in section 2.7.2. Onceprobed the membrane waswashed three times in
250mL 2xSSC. the first wash was done in the hybridization tube in the hybridization oven
at SO~ while the next two washes were done in a glass dish with gentle agitation at room
temperature. The membranes were thenallowedto air dry and placed in an Xsraycassette
with X-ray film for three nights at room temperature before developing.
Any positive clones were picked and grownin IOmL LB-carb as describedabove.
The plasmid DNA was isolated using the Wizard miniprep system according to the
manufacturer's protocol and the samples were resuspended in SOIlLof water andsent to the
Universityof Guelph for automated sequencing.
2.9 DNA SEQUENCING
Sequencing wasperformedin order to identifyandexaminesegmentsof interest such
as PAC ends and subclcne micrcsatellites. Sequences were often used to design
oligonucleotide primers.
2.9.1 Cyclesequenciog
All reagents used for cycle sequencing were from the "fmol sequencing kit"
purchased from Promega (Madison, WI). An oligonucleotide primer was radioactively
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labeled bycombiningIOpM of primer, I~L l OxT4 pNJ(buffer,S units (u)T4 pNJ(and3~L
IOmCilmL y.np_ATP in lOlll total volume and incubating at 37"C for 30 min. For each
sample,4 tubes were labelled A, C, G and T and to each 2J..1L of the appropriatedlddNTP
was added. For each sample a sequencing cocktail of 5J.1L 5x sequencing buffer, an
appropriatemassof ONAtemplate, 1.5IlL end labeled primerand lJ.1L 0£5 wu l.seq uencing
grade Taq polymerase in a final volume of 17J.1L was created. 4).1L of the sequencing
cocktail was added to eachof the tubesmarked At C, G and T and a drop of mineral oil was
addedbeforecapping. Thesampleswere placedin a Perkin Elmer 9600 thermalcyclerand
denatured by hearing 95°C for 2 min. and cycle d at 95"C - 455ec., sooe - 30sec ., 7Cfe-
Imin., 3S times and then ramped to 4"C unt il ready for use. 3JlL of "DNA Stop" solution
wasaddedtoeachsampleand 2.5-3IJLwasthen loaded onto a urea/polyacrylamide gel and
run for IY2 and 3 hours.
2.9.2 Automated sequencing
A 1.25/lg sampleof PAC DNA wasprecipitated and used in the following reaction;
8 .5~L dlU O, I~L DMSO, 25pM primer and 8~L ABI BigDye solution (Perken-Elmer
Applied Biosystems, Foster City, CA). The samples were placed in a Perkin Elmer 9600
thermal cycler anddenatured by heating 95°C for 5 min.and cycledat 95°C- 45sec., 50°C·
zosec. 60°C-a min., 55timesand then ramped to 4°C until ready for use. The sampleswere
then purified (Helix and Primer, $1.John's, NF) and run for 12 hours in an ABJ Applied
Biosystems 370A automatedsequencer using a 30w Helium-Argon laser. The gel wasrun
-42-
for 12hoursand theoutput was analyzed usingABI Sequence analysis software version 1.2.
Alternatively, the DNA samp les were dried down in a 1.5mL rube and sent to the
Departmentof Zoology at the Universityof Guelph forautomated sequencing. Sequencing
in this mannerroutinely resulted in over 600 basesof readablesequence.
2.10 ANALYZING DNA S EQUENCES
Clean DNA sequences were typed into The National Centre for Biotechnology
Information(NCBI)(http://www.ncbi.nlm.nib.govl)onlineadvancedBLASTsearchengine.
The searchesused the BLASlN program withthe nr database. Any sequences whichwere
found to be relatedto the query sequencewithan E-value of 0.01 or lower were considered
significant.
In order to search for repeat sequences, the program "Sputnik" was used
(bttp:/lwww.abajian.comlsputnik/index.html). Sputnik searches DNA sequence files in
FASTA formatformicrosatellite repeatswitba repeated region between 2 and 5 basepairs.
The program reads through the entire sequence and assumes the existence of a repeatat
every positionand compares subsequentnucleotides. If the resulting score rises abovea
preset threshold, the region along with its position andscoreis written out. If the score falls
below a cutoff threshold, the search is abandoned and begun again at the next nucleotide.
Each nucleotide that matches the value predicted(by assuming a repeat) adds to the score
whereaseach"error" subtracts fromthe score. The FASTA fonnat sequence was obtained
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from KeBI andsavedas a textfile inlJ1\1X format beforebeinganalyzed by Sputnik.
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3. IDENTIFICATIO N OF DISEASE
3. 1 J UVENILE l'OEPHRO:"OPHTHISIS I rNPH-ll
3.1.1 Results and Discussion
As seen in Fig. 5, the affected individuals in the UI family did not display HSD for
any of the polymorpbic markers within the Jl"TPH-1region nor was there any evidence ofa
shared haplotype. The LODscores significantlyruledout fouraf the markers andindicated
that it was improbable for D2S121tobe linked to the~rpH-J locusdue to the low negative
score of -1.41ate= 0 (Table 2). This findingindicatedthat none af the affected individuals
inherited two mutatedcopies aftbe l'o"PH·J and the diseaseoCthe UI family is not linkedto
NPH-l (Jones, 1997).
~ Cere pedigree of the Ul family with all affected individuals, their parents,
grandparents andother select relatives depictingtheir haplorypes for the markers
within theNPH·l regionofchromosome2. Note thattheaffectedindividuals arenot
bomozygus foranyof the markersand haveal1 inherited different chromosomes. 0
= inferred genotype,• = unknowngenotype. x =meiotic recombination.
Fig 5. VI NPH-I baplotypes
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Table 2:TwopointLODscores betweentheNPH-llocus and markersinthe NPH-) region
of chromosome2·.
Marker e~ 0.00 e~ 0.05 e~ O.IO
D25293 -~ -2.37 -1.31
02 5340
-
-2.33 - 1.20
D25160
-
-3.02 -2.24
02 5121 -1.4 1 0.76 0.93
02 5363 -5.68 -1.58 -0.074
• Reproduced fromJones( 1997).
S Recombination frequency
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3.2 J UVENILE NE PHRONOPHTHISIS II IN PH-21
3.2.1 Result s and Discussion
As seen in Fig. 6. the haplctypesfor the family, using tbe chromosome 9 ?\"PH-2
markers. did not provideany evidenceto indicate HBDamongtheaffected individualsatany
loci. The affected individuals in sibship A were not exclusively homozygous at any of the
6loci testedexcept for thepossibleexceptionof 0 95280 which is, in fact, a flanking marker.
A recombination in Indivi dual S l created a heterozygosity at marker 09591 0 whereasher
siblings are homozygous. thus ruling out that locus. Similarly , there are nc common
homozygous baplorypes among the affected individuals of sibship B or C. LOD score
analysis confirmed that tbe disease was not linked to NPH-2 as all of the scores were below
-2 at e: 0 (Table 3).
Figure 6: Core pedigree of the UI family with all affected individuals, their.gaItnts,
grandparents and other select relativesdepictingtheir haplotypes for the markers
withintheNPH-2region of chromosome9. Notethattheaffectedindividualsarenot
HBDfor any of the marker loci. [ ] ::: inferred genotype. - :::unknowngenotype. x
= meiotic recombination.
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Table3: Two-pointLODscored betweentheNPH-2locus andmarkers in Fig. 6.
Marker e= 0.00 e= 0.05 e= 0.10
D9S197
-
-1.88 -0.900
D9S280
-
-2.53 -1.53
D9S91O
-
-1.60 -0.82
D9S938
-
-1.07 -0.34
D9S2026 -3.37 -1.82 -1.21
D9S105
-
-0.96 -0.76
eReccmbinaricn frequency
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3.3 MOUSE BPK/JePK
3.3.1 Result s and Discussion
Polymorphic markers for this part of the study werea kind gift from Lisa Guay-
Woodford.Department of Medicine. UniversityofAlabamaat Binningham, Birmingham.
As seen in Fig. 7, none of the affectedindividuals displayed HBDat any of the five markers
tested. Two point linkage analysis statisticallyexcludedlinkage to the bpk/jcpk locus for all
five of the markers tested as all gave scores of - coo at e = 0 (Table 4). These results
effectively revealed that the kidney pathology occurring in the VI family was not linked to
a humanhomolog of the mouse bpkljcp k gene.
~ Core pedigree of the UI family with all affected individuals, their parents,
grandparents and other select relatives depicting theirhaplotypes for the markers
centenic to thebpkljcpkregionofchromosome 10. Notethatthe affectedindividuals
are not HBO for any of themarker loci along the chromosome. [] - inferred
genotype., - = Wlknowngenotype, x "" meioticrecombination.
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Table4: LODscores of two-po int linkage analysis on the markers in the bpkljcpk region.
Marker 8 ~O.OO 8 - 0.05 e= 0.10
0 105196
-
-4. 18 ·2.82
0105 568
-
-3.25 ·2.27
01 051756
-
-4.12 -2.62
0 105581
-
0.86 1.02
0 1051670
-
·6 .15 -4.12
e Recombinationfrequency
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3 .4 AUTOSm lAL RE C ESSIVE POLYCYSIIC KJDS EY DIS EASE
3.4.1 Results and n tscusstoe
Asseenin Fig. 8, all individualsin sibship AareHBDformarkers 065 272,D6S46S.
0 65243andD6S1714. revealinga commonhomozygous5·5· J2·5 haplotype. However,due
to a meiotic recombination in individual PIO 29, theaffectedindividuals are heterozygous
at the markerloci D6SI024, 0 65466 and 0 65295. Both affected individuals in sibsbip B
(PID 40 and41)are homozygous for the 0 65272 markerand are heterozygous for the5-5-
12-5 haplotype inherited from their father (plD 40) which is also found in sibship A. Both
individuals also share the sam e maternal chromosome through ou t the full region. Their
unaffectedsister (pID 52) does not share either of the chromosomal haplorypes with ber
affected siblings. The affec ted individual in sibship C (p ID 55) is heterozygous for all
markerstestedand does not have the5-5-12-5 haplotype seen in the other twosibships. His
unaffected sister (pID I I2) was unable to be testedformuch of the study due to her young
age; however, the marker D6S1714 was used to examine her DNA andbased on the results
it appearsthatshe and her brother inheriteddifferent chromosomes from each parent For
sibshipsAandB, two-point linkageanalysisreveal edseveralpositiveLODscores, including
two which indicatedsignificant linkage between thedisease in the family andmarkersat the
PKHD-llocus(LOD >2.0 at e=0) (Table 5). Theseresults support the possibilitythat the
diseaseaffectingthe Ul family is ARPKD. However, theresults donot conclusively rev'eal
that ARPKDis the disease in all affected individuals.
~ Core pedigree of the U1 family with all affected individuals, their parents,
grandparents and otherselectrelatives depicting theirbaplotypes forthe markers in
theARPKDregionof chromosome 6. Notethat the affectedindividuals insibship
A are IIBD for the markers D6S272to D6S1714 creatinga 5·5· 12·5 haplotype.
Affectedindividuals in sibship Bhaveonecopy of the 5-5-12-5haplotypeand have
the same copy of the maternal chromosome which they do Dot share with their
unaffected sister. Theaffected individual in sibsbip C is Dot HaD foranyof the
marker loci withinthe ARPKD region. [ J = inferred genotype, - =unknown
genotype, x = meiotic recombination.
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Table 5: LOD scoresof rs..o-poinr linkage analysis on the markers in theARPKD region.
Marker 6 =0 6 =0.05 6 =0.10
0 68272 -1.48 1.69 1.83
0 68465 2.95 3.98 3.70
0 68243 -0.18 1.26 1.50
0 681714 3.08 2.67 2.38
0 68 1024 -1.41 1.10 1.23
06S466 -3.85 0.90 1.33
068295 -2.74 1.44 1.77
From Jones( 1997)
eRecombination frequency
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It does appear that the affected individuals in sibship A (PIDs 49, SOand 51) have inherited
two identicalcopiesofthe mutated PKHD- I geneand thatthe affectedindividuals insibship
B (PIDs 53 and 54) have likely inherited two different mutated copies of PKHD· 1.
However. theaffectedindividual insibship C(PID55)didnot inherit the5-5-12-5 haplotype
present in the other affected indi viduals or the 5-17-9- 11-1-7-6 haplotype present in the
affected indivi duals in sibship B. This is consistent with the clinical phenotype which
suggests that the affectedindividual in sibship C has a different disease fromsibsbipsAand
B. It remains unclear as to what disease individual PID S5 has. Assuming that the disease
in sibships A and B is indeed ARPKD, the me iotic recombinat ion in individual PID 29
narrows theARPKDcritical regionfrom flanking markers D6SI7 141D6S243(Mucberet al.,
1994)-065466 (Guay -Woodfo rd et aI., 1995) 10 flanking markers 0 65 1714106524 ) -
D6Sl024creating a IcM critical region. These resultswere later corroboratedby Zerreset
al. (1998)whoidentifieda meioticrecombination inan individual, allowing theconfirmation
of D6S1024 as the centromeric flanking marker for the ARPKD critical region.
3.5 AUTOSO~IAL DQ~IINANT P OLYCYSTIC KI DNEY DISEASE
3.5.1 Res ults an d Discussion
As has been noted numerous times in the available literature, the most effective
method of determining if an individual bas ADPKD is to perform an ultrasound on the
parentsofan affectedchild (Ogborn, 1994; Fickand Gabow, 1994; Sessa etal., 1997;Zerres
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et al., 1998). By doing so it can be determined if one or both parents have polycystic
kidneys. If at least oneparent bas polycystic kidneysa diagnosis of ADPKDcan bemade.
Kidneyultrasoundswerecarriedoutby nephrologist Dr. Benvon Cramer{MD), Department
of Medicine, HealthSciences Centre, St. John's, Newfoundland. The only individual for
whichtherewasany suggestionofADPKDwasPID5Sinsibship Cas be did notapparently
map to anyoftbe other regions. The father, PID 38, and mother. PID 65, underwent kidney
ultrasound in order to determine ifeitherof thembadpolycystickidneys. The fatherbada
smallcystat the corticomedullaryjunction ofbis leftkidney. Otherwi se, his liver andboth
his kidneyswere normal. The motherbad nonnal kidneys and liver. The finding thatthe
fatherof theaffected individual hadacyston his kidney wasequivocal. InADPKD I,cysts
develop in both kidneys by age 30 although the onset of cystogenesis may occur later in
ADPKD 2 (patrick S. Parfrey, personal communication). Therefore, it is likely that
AOPKDwasnot inheritedby PID55fromeitherofb is parents; however, this does not rule
out the possibility of the presence of a novel mutation in this individual.
3.6 CON CLUSION OF DI SEASE IDENTI FICATI ON
Homozygosity mapping alongwith linkageanalysis on theVI familyusingmarkers
in the ~tpH· I , NPH-2 and bpkljcpk regions allowed these diseases to be ruled out as the
cause ofPKDinthis family. Thesetechniquesalsorevealedthatthe ARPKDis the probable
causeof the PKDin sibshipsA andBbutnot sibshipC. Fwther analysisofsibship C failed
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to reveal evidence of ADPKD. This unfortunately means that the cause of the kidney
pathologyinsibship C remainsunknown. It is possible thatanADPKDmutationin sibship
C occurredspontaneously in individual PID 55. Although rare, there are other examples of
several mutations leading to similar diseasesoccwring in the samefamily as was thecase
for a Newfoundland family displaying hereditary eye disease. Because there are oilier
individuals with ARPKD within the Newfoundland population, it is likely that twoseparate
ARPKD mutations are causing the pathology in sibship B (Jane Green, personal
communication). Sibships A and B in tbe VI family are informative and allowed the
ARPKDcritical region tobenarrowedto approximately a IeM region. Becauseartbi s, the
family wasconsideredpotentiallyuseful for further narrowingthe ARPKDcriticalregion.
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4. PROD UCTION OF A PAC CO:-lTIGUOUS MAP FOR TH E ARPKD
CRITICAL REGION
4.1 SCREENJ!'iG THE PAC " DOWN TO THE W ELL" LIBRA RY P OOLS
In 1997, Lens et al. published the results of a finephysical map of tbe ARPKD
region, made up of novel sequence tagged site (SI S) markersand a YAC contig (Fig. 9).
The markersspecifiedin that study weresynthesizedandusedto screenthe PACscreening
library in order to obtain a more detailed map oftbe region.
4.1.1 Initia l Screen
A totalof seven PACs wereidentifiedwhichoverlapped the ARPKDregion (Table
6, Fig. 10, 11and 12); however, theydid not completelycover the wholeregion. The ends
of some of the PACs were sequenced using the17 orSP6 primer(Appendix 3 and 4) and
subject to a BLASlN search (Appendix5). The sequences attainedwere used to produce
STS markers which enabled proper orientation of the clones and further screening
(Appendix6).
4.1.2 Second Screen
The newmarkersobtainedfromthe firstsevenPACcloneswereusedto rescreen the
-60-
[£ gJ
11 ~ ~
~ ~43 ~ 1'fMl191)f1
2l C6S1714 CC6S1253855R 11\1-13002
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~ Fine Mapof the ARPKDregionwithnew nonpolymorphic STSs and five
YAC clones coveringthe region(Lens et aI.. 1997 )
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Table 6:Resultsofin irial screenof PAC library usingpolymorphic markersandSTSs.
Marker" Annealing # of possible Final # of PACs Identified
temperature PAC, Initially PAC, Found
(OCr Found Accurately
06 51714 60 4 1 123113
0651024 45 3 1 1221c3
776L 58 4 2 101d2, 320012
LB51 55 2 2 20306,265a 14
XL03 58 2 1 146010
• From Leoset at (1997)
~ PAC"UpperPool" screening using themarkergSSR. Theexpected productwas
2S9bpinsizewhicbappearedin lanes 7, 11, 26, and 32. The table below the gels
indicates whichplateshavebeenpooled tocreateeach sample. + = Positive control
(hwnan genomic DNA), · = Negative control(dHzO).
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Gel I Gel 2
+ • I 2 3 4 5 6 7 8 9 10 11 + 12 13 14 151 61718 19 202122 •
Gel 3
+ 23 2425 26 27 282930 31 32
I . 1-10 7. 61-70 13. 121-130 19. 181-190 25. 241-250 31. 301-310
2. 11-20 8. 71-80 14. 131-140 20. 191-200 26. 251-260 J2. 311-321
3. 21-30 9. 81-90 15. 141-150 21. 201-210 27. 261-270
4. 31-10 10. 9 1·100 16. 151-160 22. 211-220 28. 271-280
5. 41-50 II. 101·110 17. 161-170 23. 221-230 29. 281-290
6. 5H O 12. 111-120 18. 171-180 24. 231-240 30. 291-300
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+ 101 102 103 104 105 106 107 108 109 110
~ Plate pool screening of the PAC "Plate Pools" with the marker gSSR. Note
that the marker amplified a fragment in 101, indicating that the PAC of interest
is in that plate. + = positive control (human genomic DNA), - = negative
control (dH,O).
fu:!!ltl1; PAC"Downto theWen"poolsforthePACindish101screenedusing the8SSR
marker. Notethat thePAC ofinterest is incolumn 0 androw2. thereforethename
of the PAC is 101d2.+ = Positive control(bwoan genomicDNA), • = Negative
control (dH,O).
Gel 1
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PAClibrary inanattempt[0 attain acompletecontiguousmap of the region(Table7). Three
newPACclones were isolated with the secondscreeningof the PAC pools givinga total of
10PACclones withintheARPKDregion. Theends afthe new clonesweresequenced with
the 17 or SP6 primers and the sequences were used to design primers for STS markers.
These markersweresubsequently used to orient the PAC clones and determine theoverlap
with other PACs (Fig. 13). Unfortunately, after the second round of PAC clone isolation a
complete contiguous map had still notbeenobtained. At this point it was decided that. due
to time constraints, there would not be a third scree;'!of the PAC pool library but rather
subcloning of the available PACs should begin.
·66·
Table7: Resultsof secondscreenof thePAClibrary usingnovel STSsgeneratedfromPAC
ends.
PAC STS Annealing # of possible Fina1 # of New PAC,
temperature PAC, Initially PAC, Found Identified
C'CJ Found Accurately
20306-SP6 55 3 2 108c2, 6Sb9
I4601o-n 52 3 1 16122
320c12·n' 55 0 0 N/A
32OcI2·SP6' 58 0 0 N/A
Due to blsb background annealing noclones were able tobeLSOLattd.
EW!lLll; Partia llycontiguousPACmapof theARPKD region,
D6S243
D6S1714
855R
771L
776L
I08c2-SP6
20306-SP6
XLOI
XL0 1
65h9-SP6
J08c2-T7
LBS2
LBSI
20306-T7
802L
693 R
146010-T7
918L
XL03
Wl-9141
D6S I024
1460 JD-SP6
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5. SEARCHI :'I'G FOR :'I'OVEL l\lICROSATELLITE l\IARKERS
'\lTHIN THE ARPKD REGION
5.1 SCREE~I~G SUBCLO~ES FOR MI CROSATELLITES
Each PAC clone was subcloned into the plasmid vector pUCl8 and tbe subclones
were screened with repetitive di- or tri- nucleorides. Seven colonies appeared to hybridize
to one of tbe three probes (Table 8). For those clones which were potentially positive, the
colony was picked and the plasmid DNA was isolated. The insert was digested out and a
Southern blot was performed using the same probes (Fig. 14).
5.2 A."ALYZI~G THE b SERT SEOUE~CES
Clones which gave strong positive results after Southern blot analysis were sent to
be sequenced (Appendix 3) in order to identify the natureof the repeat and its surrounding
sequence (Appendix 7). Only four repeat sequences were found in the subclones one of
which was considered too small to be polymorphic (161222-22). It is likely that other
repeats were present but were Dot found as the whole insert was too large to sequence
completely without creating more oligonucleotide primersand resequencing. Some of tbe
subclcnes, for example 65h9 1-9(F) and 265al 4 t·3(R). were found to contain multimeric
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Table 8: Number of subclones produced from each PAC and the number suspected of
containingsatellite repeats.
PACclone # subclonesscreened for # suspected satellite repeats
satellite repeat
320cl2 71 0
IOId2 136 0
32Ocl2 110 0
20306 464 2
265.1 4 173 1
146010 416 0
108c2 349 0
65b9 475 2
16122 497 2
~ a)Dish#2 of the: 20306 subclone colony screens. Arrows depict twopossible
insertscontainingrepealregions whicb werenamed203062-16 and 2-36. b) PAC
20306 subcloneswiththe insertfragment digestedout c) Autoradiograph of the
Southernbybridization of the gel depictedin b). Notethat subclones in lane 2 and
5 havegivenintense signals indicating thestrong possibility that there is a repeat
regionineacbofthcse clones. d)Table detailing the contents or each lane iDthegel
in b) and the Southern blot in c). Note that the suhelone20306 2-36 depicted in a)
gave astrong signal intheSouthernblot inc).
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inserts whichoccurredas a resultof the digested PAC fragments reannealing at their Sau3A
sites. Oligonucleotide primers were designed around the repeat sequence and used to
determine whether or not the repeat was polymorphic in the VI family(Appendix 8).
Unfortunately, when the primers were being designedan error was made and the S' end of
the reverse primer for 16£22 1-40 extends into the pUC18 vector by 5bp. This error also
occurred in the reverse primer of lafiolO5-37 but only by Ibp. Two of the satellite repeats
which were discovered were monomorphic in the U1 family(16t22 1 ~40 and 1460105 ~3 7)
and the third, 146010 5~37, did not work despite several attempts using different reaction
conditions. The sequenced insert regions were inputted into Ne Bl's BLASTN search in
order to determine ifthere were any previouslyclassified sequences (Appendix 9). During
the BLAST searchone of the 65h9subclones was foundto be completely overlap a known
sequence which turned out to be the I08c2 PAC clone which had been completely
sequenced, by the Sanger Centre (Hinxton, Cambridge), and entered into NCBl's database
10days earlieron September 28, 1999 (GenBank accession # AL034343).
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6. Al"lALYZING TH E I08C2 PAC SEQUE:-iCE
6 .1 ANA LYSIS "' '0 M ANIPULATION
The sequenceof the 108e2 clone was preliminarily analyzed by using the "find and
replace" function of WordPerfect to look for simple repeat sequences. Later the program
"Sputnik" was obtained and used.. The highest score which resulted from the 108c2
sequencewas 59 found at position 14662 - 14736and resulted froma CTIT tetranucleotide
repeat 75 bp in length (Appendix 10). Closer inspection of this region revealed a more
complexrepeatconsistingof di- tri- and tetranucleotiderepeatsconsisting ofCT nucleotides
with a total size of 289bp. Oligonucleotide pri mers were designed around this region in
order to determine whether or not the marker was variable (Table 9).
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Table 9: Properties of the oligos designed aroundthe I08e2repeat (from "Primer 3").
Marker Sequence Tm' ~.r.t any: 3" annealing
('C) temp. ("C)
I08c1· (F) GCAGAAGGCAGQACAGGTAT 59.3 1 55.00 2.0 2.0 ss
FULL! (R) ATGQAGTGACACCCCGTcr 6039 57.89 7.0 3.0
• Melting Temperature
t GC content of cligcccelectide
: The self-compkmenuriryscoreoftbeoligo as a measureof itstendencyto anneal to itselfor Connsecondary
structure .
a The self-complementarityoClhe: oligoas III measure of its tendencyto fonn a primer-dimerwith itself.
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6.2 GE~OTYPI~G
6.2.1 Results and Discussion
The 108c2 FULLI markerwas used to screen the DNA from the VI family and it
was indeedquite polymorphic resulting in a total of II different alleles (Fig. 15). The gel
wasscored andthegenotypeswereadded to the baplotyp es previously found in the ARPKD
region on chromosome 6 it was then clear that the affectedindividuals were heterozygous
for this marker (Fig. 16). The affectedindividuals in sibship A all inherited the genotype
2. 20 while those in sibship B inherited the genotype 2, 10 which differed from their
unaffected sibling who inherited an 18, 16 genotype . The affected individual in sibship C
inherited a genotype on , 7 whi le his sister inherited a S. 7 genotype. This indicated that the
meiotic recombination which occurred in the father of sibship A (PID29) had occurred
furthertowardsthe telcmeric end ofehrom osome 6, to at least the 108e2 FULLI marker.
Linkage analysis was thencarriedout in order todeterminethestatistical significance of this
finding (Table 10). Because it is believed thatsibship C does not have the same disease as
sibsbipsA and B, it wasthought to be prudent to determine the linkage of 108c2FULLl
withoutthe influence of the data fromsibshipC. Table 10 does sbow that the LOD scores
were higherwhen consideringonly sibships A and B; however, at 6 = 0.00 the LOD score
was still well below 3.0 without the data fromsibship C. The two point linkageanalysis
reflectthehypothesis that duetotherecombination in individualPID29,describedin section
3.4.1, the IOBe2 FULLl markercan be excludedfromthe PKHD-I critical region.
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~ a) Autoradiograph ofU1 family DNA analyzed with the 108c2 FULL!
marker. b) Identification of the DNA samples in each lane of the
a uto radiogra ph in a) a nd th e corres po ndi ng ge no ty pe .
~ Core pedigree of the VI family with all affected individuals, their parents.
grandparents and otherselectrelativesdepictingtheirhaplotypesfor the markersin
the ARPKDregion of chromosome 6 including the Dew marker 10&2 FULL·I.
Note that the meiotic recombination which in individual PID29 occurredabove
(telomeric} to the 108c2 FULL-l marker. [ J' Inferred genotype,· • unknown
genotype.x ""meiotic recombination.
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Table 10: LODscoresof two-point linkage analysis on thenovel marker in theARPKD
region.
Marker 6~0.00 6 = 0.05 6 =0.10
108cH ULL! (Sibships A. B and C) 0.05 1.77 2.02
108c2 FULL! (Sibships A and B 1.48 2.23 2.11
only)
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Using a contiguous map recently produced by Park et al. (1999) it was possible to
estimate the size of tbe region between I08e2 FULLI andD6s1714JD6s243 which contains
tbe PKHD-l gene. Through knowledgeof the sizeof eachof thePAC or BAC clones found
within this region it was possible to estimate the distancebetween each of the markers. By
doing so it was estimated that a region of 516Kb between markers 108C2FULLl and
D651024 could be ruled out and the critical regionnow liesber.... ..een thel08C2FUlL I and
D6517141065243 markers. a region of approximately 560Kb in size. This finding was
significantas it essentiallycut the size of the critical regionin halfleaving a relatively small
region to be screened forexpressedsequences. It isestimatedthereare 20·25genesper Mb
(Fields et al., 1994). Therefore it can be inferredthat only I I - 14 genes remain to be
screened for mutation in individuals affected by ARPKD.
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7. CONCL USIO N
Homozygosity mapping with polymorphic markers for several PKD loci made it
possible to determine if the affected individuals in sibship A were HBD in a particular
disease region. IIwas also possible to determine that even though the individuals in sibship
B were not HBD, it is likely that tbey have inherited two different mutations of'the PKHDI
gene. Otherindividualswithdifferentphenotypic variantsofARPKDinNewfoundlandare
known toclinicians. Therefore it isquite possible foraffectedindividualswhoare not HBD
to inherit different mutations of PKHD I (Dr. Jane Green, personal communicati on). LOO
scoreanalysis aftbe resultinghaplorypes enabledtheeliminationof threepotentialdiseases;
~'"PH- l and-2 onchromosomes 2 and 10. respectively, and a diseasesyntenicto the mouse
bpkfjcpkgeneonhumanchromosome10(Fig.5, 6and7). Thekidney pathologyinsibships
A and B was linked to an area of chromosome6 which is knownto be the location of the
ARPKD gene, PKHD·I , and suggested the presence of two separate mutations. Affected
individuals in sibship Awere homozygous forone haplotypeand theaffected individuals in
sibship B each had one copy of this haplotype and a copy of another haplotype. Initial
analysis of meregionusing knownmicrosatellite markersrevealeda meiotic recombination
on PID 29 which was inheritedby all three of his affectedchildren. This enabled the
narrowing of tbe centromeric end of the ARPKDcriticalregion to a IcM region flanked
centromerica1Jy by the marker 0 651024. The region was previously determined to be
flanked by the markers 06524310651714 on the telomeric end of the region by Guay-
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Woodford et al.(199S){Fig. 8). The affected individual in sibship C (PIO55) did not share
either of the common baplotypes seen in the affected individuals of sibship A and B. This
confirmedtheclinicaldata which indicated thathe had a differentdisease, possiblyADPKD.
Kidney ultrasound failedto reveal any significantcysts in theparents of PID55. indicating
that AD PKD was not inherited by this individual from his parents. However, this does not
rule out the possibility of a novel mutation of the ADPKD I or 2 gene. This will only be
confirmedonce this individual can be screened for a mutation in each of the two ADPKD
genes.
Uponproductionof a PACmap andscreeningPACs for microsatellites, new repeat
regions were found within the critical region but they were not variable in the UI family.
The elucidationof the complete sequence of the I08e2 clone by the Sanger Centre and its
publication to the public domain led to the discoveryof the novel repeat sequence I08c2
FULL~ I approximately 14, OOObp from the telomeric (SP6) end of the clone. Analysis of
the UI family with this new marker revealed that it was highly variable and informative.
The analysis revealed that the recombination in PlO 29 which allowed the narrowingof the
ARPKDcritical region to a IcM area had occurredfurther towards the telomeric end of the
chromosome, producinga new critical region of approximately 560kb.
Future research in this area will focus on finding expressed sequences in the critical
region using the techniques of exontrappingandkidney eDNA libraryscreening. Screening
can be done using the remaining PACs in the critical region, 320c 12, 101d2. 123b3 and
others named in Park er aI. (1998) as probes. There are genes in the region which have
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already been ruled out as the PKHD-I gene. They include; the alpha subunit of the
metalloendopeptidase meprin (Jiang er al., 1995), glutbarhione S-uansferase (Board and
Webb. 1987), methylmalonyl coenzyme A mutase{Dib et aI., 1996) (reviewed by Zerreset
aI., 1998). retinal degeneration, slow and casein kinase II. Psubunit (Macher et ai., 1998)
and most recently, the KlAAOOS7gene whichencodesa TRAM-likeprotein(Onucblc etal.,
1999).
Giventherelativelysmallcritical regionforARPKDand thenumberof investigators
working on finding the PKHD-I gene, it is entirely likely that the gene which causes the
disease will be found within the next 6 to 12 months. In fact, there has already begunan
intensive search by an international consortiumof laboratories whoappear to bequiteclose
to findingthe PKHD-l gene. Once thistask hasbeenaccomplished. researchwill thenfocus
ondetermining the structure and functionof megeneproduct and findingmeans tooffset the
effects of the disease.
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APPE NDICES
Appendix I: Characterization of the :\licrosateUite Markers Used in Haplon:pe
Polymorphic markerswithin theNPH-l region.
Marker Coordinate Natureof Minimum Maximum Maximum
Name" (KcM)" Repeat" Lengt.h(bp)' Length (bp)+ Heterozygosity'
DZ5Z93 140 Dinucleotide 167 191 0.84
025340 14Z Dinucleotide 149 173 0.71
02 5160 145 Dinucleotide 204 218 0.79
DZ51Z1 146 Dinucleotide 156 184 0.83
D25363 148 Dinucleotide 254 264 0.69
Polymorphic markerswithinthe NPH·2 region.
Marker Coordinate Natureof Min. M",. Maximum Annealing
Name' (KoMj" Repeat' Length Length Heterozygosity' Temp. (0C)
(bpJ' (bp)'
09 $ 197 100.8 Dinucleotide 199 2 15 0.68 55
D9$ 280 102.0 Dinucleotide 0.63 55
09$910 104.5 Trinucleotide 107 55
095938 1l0.9 Tetranucleotide 370 55
0952026 117.3 Tetranucleotide 127 55
D9SlOS 120.0 Dinucleotide 187 203 0.80 55
-99-
Polymorphic markers withinthe bpkljcpkregion.
!o.1arker Coordinate ~atureo f ~1 i.'1. !o.tax. Maximum Annealing
Same (Kc:Ml- Repeart le ng-.b. L"'gth Heterozygosityt Ttmp. ("C)
(bp) 1' (bp)!
01 05196 77 Dinucleotide 101 990 0.79 58
DIOSS68 79 Dinucleotide 152 0.73 55
010 S 1756 83 Dinucleotide 0.84 55
D1OSS81 90 Dinucleotide 144 0.80 55
0 10$ 1670 94 Dinucleotide 0.76 55
Polymorphicmarkerswit hin theARPKDregion.
Mark:erNamc' Coordinate Nance cf Repeat' Min. Length Mu. Maximum
(K<Mj' (bp)' Length (bp) ' Heterozygosity'
0 65272 75.0 Dinucleotide 180 196 0.73
0 6546 5 75.0 Dinucleotide 184 198 0.75
D6S243 Dinucleotide 170 250 0.72
D65171 4 75.0 Dinucleotide 127 0.65
0 65 1024 Trinucleotide 121
D654 66 79.0 Dinucleotide 108 119 0.71
0 6529 5 80.0 Dinucleotide 93 107 0.74
a Bold indicatesnearest flanking markerto criticalregion
• FromGtnethon(bttp:l/gopher.genethon.fr/genc:tboll_en.banl)
t FromGOB (http://gdbwww.gdb.org!)
. Informationnot available
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Appendix 2: Quantification of DNA at each step ofOiagen PAC D:"iA isolation
Duringtheprocessof PAC isolation usingQiagen tips, anexperimentwascarried
out in order to ensure DNA was not being lost throughout the processand to ensure pure
DNA was being isolated. Essentially thecell lysate was applied to the calibrated tipand
allowed to run through. The tip was washed twice andthe PAC DNA was eluted (see
materialsand methods). A ImLsample of eachwashbufferwastaken in orderto quantify
theDNA whichbadcomeoff, inadditiontbeeluatewascollected in Iml samples(I5mL
total).
Sample Sample concentratio n To",1DNA (~g)
(mglmU lmL sample)
lysate flowthrough 0 0
wash 1 17.6 176
wasb2 5.2 52
eluate1 2.0 2.0
eluate 2 1.6 1.6
eluate 3 0 0
eluate 4 0 0
eluate 5 8.8 8.8
eluate6 17.2 17.2
eluate 7 6.8 6.8
eluate 8 3.2 3.2
-101-
eluate 9 4.4 4.4
eluate10 2.0 2.0
eluate II 2.0 2.0
eluate12 0.8 0.8
eluate 13 1.2 1.2
eluate14 0.8 0.8
eluate15 0.8 0.8
Theseresultsshowthattherewasno detectable DNA beinglost in theflowthrough
whichis important as it indicated thatthetip was notbeingoverloaded. The cleardropin
eluted DNA after 9mLledto thedecision to elute with IOmL elutionbuffer which would
create a higber concentration of PAC DNA in tbe eluate and allow for more effective
precipitation anda"cleaner"endproduct.
Appendix 3:Sequencing Primers
Primer Name PrimerSequence(5' - 3')
17 CCGCTAATACGACTCACTATAGGG
SP6 GGCCGTCGACATTTAGGTGACAC
Universal GTAAACGACGGCCAGT
MI3 (-48) AGCGGATAACAATTTCACACAGGA
-102.
Appendix 4: PAC end sequen ces
I23bJ -T7
CCTGGTTGGAATGGTGATGAACATTTGAGCATGACATCCTGGTTTTTGTACAA
GTTTTCTATTGCTGCTATAACAAATTATTAACAATGTAGTGGCTTCAAACAAC
ACCTAAGTATTATCTCACAGTTTTGTAGGTCAGAAGCTGGTGAACTTGGCTAT
TTTCCACTGGCTATTTTCTCTGCTTCAGATCTCTGATGGCCAAAATTCAGGTA
ATGGCAGGATTGTGTTTCTTTCTGGAGTTCTGGAGATGATTTCACCTTCAGTC
TCACTCAGGTCTGGCCACATCAGTCCATGTAGGTGTAGGACTGTGGTCGTGTA
ACCGCCAAGAGTCCGCTG
123bJ-SP6
AGAAGGATCTGTACTCATTCCCTATAATAAAATGCCAAACCAGAAAAGTCAC
AATTTCTTGTGAAATTCAAGTACACTCCTTCTTAAGAAGAGGCTTTAATTGCT
ATTAGATGAGACATGGCAAACAAACTTGTTACCTA...GTTATAACAACTATAA
CATGGCCATGGTCATACATATGTTTAATATATTATCATAGTAGTCNTATATCA
CTGCATATAGCATCTATATGGATGGTCAGAGGTGTGCCCATGAGAGTCGCA
J20cl2 ·T7
GATCCACCATCTTATCTTGGTGCCATCCCTGACTTGCCTTCTGTTCATAAACGC
CTATTAAATGTTTCTTTCTGAGAAACTGGATTTGTCAGCCTCTTTCTTTGGGTA
-103-
TCTCAGGTTCCTTGGCCTTTGCGGGTAGGTTTATATAGACCTGCTCAGCACAG
GACAGGCAGTTTCTCAAAAAATTGAAAATAG.~TTACCAAATGATCCGGCAA
TATCACTTCTGGGTATATAGCCAAAATAATTGAAAGCAAGGTCTCATAGAAA
TATTTGTACACTGATATTTATAGCAGTGGTATTCACACTCGTCAAAAGATGGA
TGCAGCCGAATTGTCCATAGGCAGATGAATTGATAAAATGTGGTATATACAT
ACAGTAAAATATTCTTCAGCCTTAAAAGAAGAAATCTACACATGCTACACAT
TGGATGAACATTGAGACATNTGCTTAGTGAATAGCCKGTTTGAAGACATCCT
GGTCTTNCTTTTTGA}c~CGTCAACNTGGTAGCACCTATTTGACCAGGN~~CCN
GGTTCCCGGCTTNGAAGGGAAATGGAA~~~~~AN~CTTTN
NANNAAAAATNCCCAANTITINfNCNCTTC (GenBank AccessionNumberAQ53751)
320cl2-SP6
GAAGGATCAAACCTCCTTACATAACATCAGGGTGTGTCACAGATGATTGGTG
AGGTGCACTGAGATCAAAGTTAAATTATACTTAAACATCAAACTCTGGGTGC
CTTCAAATTCTTTGATGACTATCATAGGAAAGAGTTACATTCACTAAAATAAT
TAGTCCACTCTTACCTATCTTCAGCCTAACTCAGGATTACACTGAACTGAAAC
CCGCTGGGGTGCATTTTCCAGAAAAGGGCCAAGAAAAGGTAGCAGGAJcAAA
TTACCAAGTTGAATGGGAAGGTAATGA(GenBank AccessionAQ5375 10)
lOld2-T7
(GenBank Accession NwnberAQ3211 86)
-104-
101d2·SP6
(GenBank AccessionNumber AQ321 184)
20306-T7
TCAGATAGCCATCCATACTTAGTTTTTCTATTTAGATCCCCTGCCAAATGGCC
AACTGGGAAAAGTAACCATGATACTAATTTCACATACAGGATGCTAAAGAAC
TGTGGTTAGTCAGATTAAAAATAAAAATCATGATTTTCTTGTACTGTCTGTCT
ATTTTATCCATTT~~TGGTGGAATGGTAGGGGCTCAC T~~GCTAA TTTGATT
TTCATTAGGAATTGCTCATGCCATTTTTTCCTTTTTGTTTACTTTTAATAATAA
CAATTCAGGGAGCAAATAAATTAACCCATGTAGACAAAAAGAGATGTAGAAAT
(GenBankAccessionNumber AQ4I8637)
20306-SP6
TACTTTGAACCTAGATGACCCACTCCAACGTTCAGCCTGCACGCCCCATCCAA
GCAGTGCCTCCCAGAGCTGATTTCTGTCAAAGCCATGAGAATGTGGTTGTGG
GAAATGGTTACAGGGCTTCTGGTGTTGTCACCACTATAAACAAAGTCTGGTCC
TCACCTCAGGCCATACAAAGGGCTGCGGCGTGTCACCTATAGATAGCACGTA
ACAAAACCACAGAGGTAAGCCAGTGGAATTCAGAAGGCTCCGAATATGTTCA
CAGCCACAACCCCAGAACAACTCATAAACTCATTTTTGGCTAATGCATTGATT
TTCTTTGGCTTTCAAAACAAAGAATTTAAAGGNGGAAACATTCATTCACAGG
CTCCTGCATAACCACTAAGACTAAAACAGCTCCGCTTGGAACTGGGAACTGC
-105-
CCCT~~TGCTTTACATGAATATATTTCTTTTNAATCCACTTTACAATCCNTAT
GAGM-1CN (GenBank AccessionNumber AQ418635)
265al4-T7
(GenBankAccession Number AQ490107)
265al4-SP6
CCTNTTAGAGGGTAGGAGGGCATCTNATCTCTTTTCAACGTAGAGTTTATGAA
AAGAGCACAACAGCTTTCTGGTGGGCCACAGAGGAGGCTAGATGGCTGGNG
CTTTCCGTGGAGCC ATGGTCTTh~CC CTATNNNTNTGG TTTACTA~~~
NTCACCACTAGAATTGCGAGGCAGACGGTGAATATNANACCTTTGCACCCAA
AGATGAAGGTGCTTGCNGGTNGATGAGTTGGTT (GenBank Accession Number
AQ490105)
146010-T7
GATCATCTGTGATTAACAGAAGAGAACACCTTAAAATAATGGGGNAGAGACA
AATTAACTAGGTACTAAGTCAGATTTCCAAGTGAAAAAGACATGAGCAAAAC
TTCTGGTCTTAATTCCTC~TAAAATGAAAAT~TAAAATGGTAACAGAG
TGACTTTCTCT~TTTTTTAGGGAGTTTGTTAC~CCTTTGGGCTTTACAGG
CATGATTTCATGGATTCAACACGAATTACACTGATATTTAGCCTTCATTTCTC
ACTTCT~GGGTGGGACTTACCTGCTGTGCCAGAGTAGGCTTCCAATGCTA
·106-
GITGGITGCTAATGTCCAT(GenBanIc AccessionNumber AQ373S76)
146olC-SP6
TNtAGCTCTCTGCAGCCTAACCTCTGGTGCTCAAGTGATCCTCCCACCITGGC
CTCCAGAGTATCTAGGACTACAGGTGTGAGATGGCTACATCTCTCTITITITT
TCITITTGAGACAGAGTCTCACCCTGITGCCCAGGCTAGAGTGCAATGGCATG
AGCTCGGCTCACTGCAACCTCCACCGCCTGGGITCAAGTGAITCTCCCACCTC
AGCCTCCTGAGTAGCTGGAAITACAGGCATGCGGCATCATGCCTGGCTAATIT
ITGTAITITTGTAGAGACGGGGTITCAACCATGITGGTCATGAACTCCTGACC
TATGTGATCTGCCTGCCTCACCTCTCAAAGTGCTGGGAGTCAAGCGTGAGCCA
CTGCACCCAGCCTGGCTACATTNCITAACCTCTCTGTACCITAAGGTNCCAAT
GTGTAACCTGTGGGCTGATAANGGANCCITGGTGATAGAAAGTCCTGGAGGA
TGATGACCCATNTN~GTAANCCCTGNAA~~GGCCNGGTITtTAAGGCITAAT
NCTTNGGGITTTGGG!'<TINITTNITITNNAAAAGGITTTTTITCCNNNITANTN
AGGITTTGTNCITAACNTCNTNAGNCAA TAA~~AACNCCN TCTTNANCC
NGNTITTNCCCCCTNNTTGTAITTTCTTCCTITTNNNCNNCCCCCCCCCNTA
(GenBanIc AccessionNumber AQ373S74)
122k3-T7
CANCAAACATGGGTGTCACATGAGGITCITGCATGGAATGTGGCTGACGTIT
CCTITGGACCATGGGACCACCACCCTCCTGGCCCATGCITCCITGCTGCCATC
· \07·
TTTTCAGGTATGTCACCTTCCGCTGTGCAGACCACTGCTCCTGAGCGCTGGGG
TGTACTTTGGCTGTTGGGGCAACTGCAGCAGTGTCTGGGCCCACCTGCTCTTT
AGCAGCCTTAGCTTCGCTTTGGGGCCAGGCACCTCTAAGTGCAAGGCTGTGCT
AGCTACACTGTGCTTGCTGGGGAA (GenBank Accession Number AQ342807)
12lk3-SP6
TGGATTTTAGATGTGTTTGTCAAATACTGATTCTTTTCACTTCTCCATGGAGTT
TTTTATTATATTAATGTTTATATTTTTCATTTCAAA,ACTTTATTTGTATCTTCTT
CAAATCCATATGCTCTTTCTTTCTATATGCCTTTTGTGGAGTACTACTTAGGGA
AAAGTGGGAGCAGGGAAAAGCAAAAAGAGAAAGCAGTAAGCTACAAGTCTG
TCTTTCTTCATGGTCCAAGACACATAATACTCCTGTGCAAATAACTCACAATC
TTCCCGTTCCCAACTATCACCAGACACCTGCAAGTCAGCTCACTTCAATACGG
CGTTATCAGTACTGCACAATAGTCCCCTTTTGANACAGCATANACACTATCTA
TAAAATCTCCAGCAAGCCTTTGNTTCTTTGCAGCCAGNTTCTTTTNTGGANAN
CCNGCCCATTGCTTCTTTANAAAAAAGTTKTCNAATTTTCNT~~AAAAAA~~
NNNNCTTTTTNAANNNNCCTTNGCGANATTNTNTCCCNCGTNTCNTNC~~AN
AGNNCTNAATNANCCTNAATh~CTTGNACTNCC~~ACCNTTTCNC
NTNTCTAATTATCATTKC~~CC~~GTN~~CTATNNTTCCTCCC~~~
NNCATACNTNAC~~CTTATNTNCTTTANTTNTCNTCCTACTNGTCAC
TCCTCNTTTCTNNCTCCTh'TCCCCCNNCCAAAC (GenBank Accession Number
AQ342805)
-108-
108c2-T7
(GenBank AccessionNumber AQ318321)
108c2-SP6
CAATGATCCTAGCCTTGTCACAGTTAGATTGTCCAAGTAAGGGTACCTGGCCC
AAGCTTTGCCAATTAGATACCCTNCAAGAGGAATTTGGATTAGGTTCATCCTT
GCTATGTGA TATTTTGA~CAACAACAACAACAACAAAAAG TAAACTCAGGCG
ATGTTGGCAGCATGCTAACTGGAAAACCAGGTGAAACTTGTCTCAGCAGATG
ACAGAGATAAGAGAGTGAACTAGTTCTAAAGAGAAGAGCAGCTGCAAGAGA
TGAATCTAAATTCTTAGGGGCATTCAAGTCCCTGCTTCCATTCATTCTGGCAA
GCTGGCTGTATCTCTGCCCTTGACTTCCATTACATGCCCCATGTATCTTTATGT
GGTGAGCTATGTATTGAGGTACCCATATTCCTGGTTATTGGANGCCAATAATC
GGAAGNAGANAACTTTTTTGGTTCNTCCATTCTCCTTANTGGCCTCCTTTACC
ATTTACCACCCC~llTTANCCAACCCAGG NTCCTTGNATCCNNTTNGNN
NNTTCATTGCTAANACCTTNGAAANC TTCNTTTTAACC TTGTCC~~CNTNA
NNCNTTNTCANGGNTCCCNNATNTGGAAAANNNNC (GenBank Accession Number
AQ31831 7)
6Sh9-T7
(GenBank AccessionNumber AQ 1941 13)
-109-
6Sh9-SP6
CAAGGATCCTTGAAATCAAAATAGGATTCTACTTTAAAAACGGAAATATCAA
AAATAAAAAAAAGATTATCTTGGAAATTAAAAACACCATAACTGAAATGAAA
CAGTCA~TAGAA TCCTGGAAGAGAAAGTTGAAAACATCTTCCAAAAAG TAGA
GCAGAAAGATTA~TATGGGAGAAAAGATCAGGGG TCCTATCCAGGAAG A
ACTACTGTATATCAGAATAGAAAGTGAGTAATGGAGTAAAACAGTGAGTAAT
GGAGGAGAGGAAATCAGTA~CTAAACACATGAAAGAAAATCCCCAGAACTG
AAGAATATGAGTTGCCAGAGAAAGACTCATCAACTGTCTAAATGAAGCACTN
ACACCAAGCCACATCTTAGTGAAATTTTCAGAATNCTGAAGGCAACCNGAAA
ATCTCNGGCTTTTGGGAGAAACCGGTCAGTCCNANGGCCGATTCCN~CCT
TTNNATTTANA TGGCCCTTACCTTANCA~~GGNAAANTNCCC CAATTCCNA G
GGAATTTTTTCCN~AAACTCCCNNCCNTGNANTTTTTN C~~GGGAAAAA
ACTTTCTTNTAN~~CAAATTGCCCNCCCTTTTCCC(GenBank AccessionNumber
AQ237184)
16f22-T7
(GenBank AccessionNumberB82490)
16f22-5P6
TCAGACTTCAGGTAAAAGCATCTAGATGACAAATATTTTTTAAAAATACAAA
-110-
GAGGTAAAAGATGAGTGTTTTGAATGAAGGCTGTTGCAATATGGTTTGAGAT
~~TGGATATGAGGTGTCTATTTTGCAAGTCTAGACACTTAGATGTGAAAAA
TGAGGCAA~CAAAGCAT.~~GATGACTTCTATGTTTTTAAGATGTGGGAA
TATTGACTCAAATGAGAAAGACTGGGAGCAGGACAGATTTGTGAAAGGAGC
AAATGTATTTGTGAAAGGAGCAAAAGCATCAAATCTCTGAGAACACAGGGAC
CACCGG.~ATCCAGGTAGAAGTGAAAAACTAGAGACATAGGGACGTGGA
AGCCACTTCTGCCTGAGCACACCTGCCAGTCTAAGCAAACGTGAACTCTGATT
TTTGAACCTCATACAACACGAAAGAAATAGGTGTCAAACCCAGGACCTACTT
GAAGTGAGAATTAAGAGAAGACCTTCTCTGGCTTGTCAGACTTAAGTGATCC
TCCTTTATGGTAACATGACCTGAAATAACATGCCTACCCCGATTCCCAGG~GA
TTAAGGN~AAAAAAA TC:-'TIGNTAGTTTTAl'CCANTANCOo,GGGI\'TTTG
CTh'NTCo.~CAGGCTCT AANl'CASl>GAATh'CCGTTCA:-"CTTTGAAAAA
ATTTh"Nl\001'o1'o1'CCTh1'CCl'CCCl\CCC (GenBankAccession Number 8 85351)
Appendix 5: PAC end sequence BLASTN analysis
20306 - T7 Nothingsignificant
gbiAFOOl950jHSGNRHRI Homo sapiens gonadotropinreleasing bo... 80 8e-13
-111-
gbIAFOO I950IHSGI\i"RHRI Homo sapiens gonadotropin releasing hormone receptor
(GNRHR) gene,
exon 1
Length= 5687
Score =79.8 bits (40), Expect =8e-13
Identities =56/61 (9 1%), Gaps = 1/61 ( 1%)
Strand = Plus / Plus
1460IO-SP6 Nothing significant
16122 - SP6Nothing significant
emblAL034343.l7 jHSI08C2 Human DNA sequence from clone 108C2 on chromosome
6pI2.i -2 I. i , complete
sequence[Homosapiens]
Length= 130904
Score = 724bits (365), Expect = 0.0
-112-
Identities · 437/451(96%), Gaps = 9/451(1%)
Strand • Plus / Minus
lllbJ..:..TI Nothing significant
~ Nothingsignificant
~Notbing significant
22M.:.TI Nothingsignificant
~1I:olhing significant
~ Nothingsignificant
J..llkJ...:.TI Nothing significant
emb/AL034343.17IHSI08C2 Human DNA sequence from clone IOSC2 on cbromosome
6pI2 .1-21.1,
-113-
complete sequence [Homo sapiens]
Length = 130904
Score = 486 bits (245), Expect = e-135
Identities = 276/284 (97%), Gaps = 2/284 (0%)
Strand = Plus/ Plus
Appendix6: NovelSTSswithinthe ARPKDregion producedfromPACend sequences
Marker Sequence (5' - 3') Produ c t Annealin g
Size (bp) Temp. ('C)
20306-SP6 (F) GCCTCCCAGAGCTGAITTCT 178 55
(R)TCCACTGCTTACCTCTGTGG
20306-TI (F) ITT AGATCCCCTGCCAAATG 164 58
~) GCITTAGTGAGCCCCTACCA
320c12-SP6 (F) ATGATTGGTGAGGTGCACTG 207 58
~)CCTTTTCTTGGCCCTTTTCT
320c12-T7 (F) TCCCTGACTTGCCTTCTGTT 188 55
~) GATATTGCCGGATCAITTGG
146010-TI ~)CCAAGTGAAAAAGACATGAGCA 211 52
~)GCAGGTAAGTCCCACCCTTT
108c2-SP6* (F) CCCAAGCTTTGCCAATTAGA 254 55
~) GAATGGAAGCAGGGACTTGA
Thepnmen for the 108c2 STSweredesignedto incorporateasmallmJcrosatelhtetnnudeotlderepc:atwhich
was laterdetermined to bencnvariableinthe Ul family.
-114-
Appendix 7: Subclone sequences
The ligationsite between the Ba.-nHIdigested pUC18 and the Sau3Adigested PAC
DNA producedaGATe sequencewhichis inbold. Any repeatsequenceswhich were found
in the subclones are in bold and underlined. Primers created around repeat sequences are
underlined and a description is given in appendix 6. An asterisk (-) eitherbefore or after a
GATe sequence indicates the beginning or end of the insert.
20306 2-36 (Fo rward)
CTAGAG"GATCACGATITGAGCATCAAGATGTTCTTGCTGGCAAAATGTTGAT
TTCTTCCCTTAAATGGTACAGATGTCATGGCAATATCAGAGAGCAAGGCATA
ATGACTTAGTGTGTGGACGCTGGAGCCAGATGCCGGGTTAAAATATCAGTTC
TGGACCTTACTAGCTGTACTAGTTGCTAATGATTTGGGTCTTGTTACCTAGCC
CCTCTGTGTCTCTTTITCCTCATATGTAAAATAGAGATGATAATAGCGCCTAC
TTCATAAAGTCATTGAGAGAATAGAATAATAATCTATAAGGTACTTGGAATA
GTTACTGACATGGTAGGTGTATTGTITAGTGTATTATTAAGAAAGATAAAATC
CATCTATTATTCTACCACAATAATAGATCACATTAATGTTTTTCTTTCTCTTCT
GCTCATTTGCCTCACAGATATATATTITATAAGGCTGTAACTGTAAGATACAT
GCAATTTGTATITGGTAATTTTTAACTTCACATTATACTCTATGTATITCCAAT
GTITCCATAAAGTATTCACAATGATTTITAGTAGCTGTGTAATTCTTTCAAGTT
GATGAACCAGAATTTATITAAGTTATTCTTITATTTTTGGACCTTTAGCTCCAA
AAATAAAAGAATAATTATTAACTTTAAAAAGTTAAATAATGCTTGTAACTGTT
-115-
TTAATTACTTTTTAAAATTATAAACTATGTGATACAAACAGAAGAGTTTATGT
CTTTGCATATGGATAGTTGCCTTGAATATCAAAATTCTGNACCGTGTGGGGGN
GGTTTCATATCTAAG
203062-36 (Rev-erse)
CCCGGGoGATCCTCGGCAAACGCCCGTGGTATTTGCGTCTGCGCGGCAAGCT
GTACTTGCTGCTGCAACGTAATGCGCTGCGTGCACCAGATCCCACTCCAACG
TTCAGCCTGCACGCCCCATCCAAGCAGTGCCTCCCAGAGCTGATTTCTGTCAA
AGCCATGANAATGTGGTTGTGGGAAATGGTTACAGGGCTTCTGGTGTTGTCA
CCACTATAAACAAAGTCTGGTCCTCACCTCAGGCCATACAAAGGGCTGCGGT
GTGTCACCTATAGATAGCACGTAACAAAACCACAGAGGTAAGCCAGTGGAAT
CAGAAGGCTCCGAATATGTTCACAGCCACAACCCCAGAACAACTCATAAACT
CATTTTTGTCTAATGCATTGATTTCTTTGGCTTTCAAAACAAGAATTTAAAGGT
GGAAACATTCATTCACAGGCTCTGCATAACCACTAAGACTAAAACAGCTCGT
TGGAACTGGGAACTGCCCTAAATGCTTTACATGTATTATTTCTTTTAATCCAC
TTTACAATCCTATGAGACAGACATTATCACCCCGCTTTATAGTTGAGGAAACT
AAGACTCAGAGAAAATTAACTAATTTGCCCCAAGGTAGGGCCATTGATNTTA
AAACACACACACACGTTCCAGAATTTTTGATTNTTCAANGNAACTATTCCAT
ATGCAAAAGACATAAACCCTTTTTGTTTGNATTAACAATAGNTTATTAA·nrrr
AAAAAAGTAATTTAAAAAAGTTCCAGCCTTTTTTNAACTTTTTAAAGGNANA
ATNTTCTTTTTTTTTGGAGCTAANGNNCAAAAATAAAAAATTACTAATAAATT
-1 16-
TfGGTfATAACTTNAAAA
265al4 1-3 (Forward)
CTAGAG'GATCATATGCACTGACTKAGAAAAGGAATGCACATGGGATGGCAA
AATAGAGAAGGCTTNTfGTGAGTGTGTGGGGGAGGCAGGATAGGGTfATCTG
GGTCTTfAAAJVL~CACTfGACTfAAGCAGAGA GGGCTATGAGAGGGCTfAA
TAAAAGTACAGAGGTAGAAATACAGAAGAGGTATAAAAATAACAAATAGTC
TfATGTGATfACAACTfGACATATGTAATTfAGCGGAAGCATfTfCTACTfCT
GAAACAAATfATGATfAACACTfCCTGTAATAGGTTfATAATfATGTAAACCT
ATTfAAATCAATCATTfGCACAACAAAATGAATGAATfAATTfGTfGCAGCTG
TGTTfACTGAGGCACACATGTAAAGCAATfTfAAATGTfGTCAAGTAACAATG
ATTfCGTTfCATGACTCACACTAAGTGAGAAATfCTGATTfTfTfAAGACAAA
GTTfAAAAAATCAAAAACTfAAAACTCCTGGAACTAAAAGCATAGAAGAAAA
GCTf CATGACATAGGACATGACAATGTGTfCTCACATATGACACCAAAGCAC
AGGGAAAGAAAGCAAAAGTAGAAAAGGGACTATATCAAACTCAAAAACTTf
TGTGCATfGAAGGACACACCTAACAGCCTGAAAAGGCAACCTATGGAGTAGG
AGAAAATATfTfGCAAATCATATATATCTATACATATATATGGATATGATAGT
AAATfGTfATACAGAAAATNTAAAAAGACTTNTNTfACTNAATAACAAAAAT
CAAATACTfATfTTTTfAAATGGCTAA
-117-
265014 1-3 (Reverse)
CCCGGG'G ATCCCAGAGGAATCACCAGACTGTATTTCACAATGATTGGACTA
ATTTGCACTCCCACCAACAGTGTAAAAGCATTCCTATTTCTCCACATCCTCTC
TAGCATCTGTNGTTTGCTGAcrnnTAATGATCAAGGAATAGCAAAGCTTTGA
GAGTGGCACCTGCTTTGTGGAAATGATACCTACAATTTTAATTTCCTTTATCT
CACTCTACTAGCATTTCCTAACCAATTTATAGAAACTGACATTAAATAAAGTT
AAAGTGAAGAGCTGQCCTATCAGTCATTGTGTGTGTGTGTGTGTATGTGTG
TGTGTGTTGCACATACCANATGTATATACC_~GAAGTGTTTGTATTCTTTAA
ATCTTGGATTTTATACTGAAGGTTATAATGACCCGGATTATCTGAATGTTTAC
ATTTAAAAATGTGGCCAGGAGACTTTAAGCAATGAGAGTCCTAATGCAAATG
TGTGATGAAAACAAAATCATGACAATGTTGTNTTAGAGATTCATCAAAGCAC
AAACGAACATTGGCTCTTGATAGATGATGTACATTGGGTCAATGCTAGCCTTT
TGATTTTCACCTCACATATTTATCCATCGNAAACATGAANGGGGTAAGCTTTC
CTGCTTGTGTAGAAATAGNCAGGAACACCTGGGATTAACTTCNGATGAAGAC
NCCTAAATGNGNAATTNGGAAGGGTAAAATTTTATTTTGGCTGGGTAATNTN
AAACCCAGCNCCNTCTTCTAAAGGGCCNAGGNCCTTTTTTGGTNAAAATGGG
NAANTTGGGTTTAAACTTTTTAAAGCCCATCCCTTTCCTAAATTTGGGG
203064-22
This clonegaveacleansequenceforthepUC18 vectoratbothendsbut thesequence
data clearly indicatedtwo insertsequencespresent This indicated that the bacteriawere
-118-
transformed with [\\'0 separate ligationproducts. A cleansequence was not attained.
161222-22 (Forward)
CTAGAGoGATCACGCCAGATGCAGTATGTGTGTGAGAGAGAGAGAGAGACA
GAGTGTGTGAGAGTGTGTGCAAATGTGTGTGAGCATGTGTAAACGCATGCAT
GTGTGCGTGCATGTGAGTGTATGCATGTACGAGTGTGAGAGTACGTGCAGAT
GCATGTGATTGTGTGAGATTGTGTGTGCATATGTGAGCATGTGTGAGAACATG
TATAAGTGCATGCGTGTGTGCATGTGTGTGAGTGCATGTATACGTGTTTGAGA
GTATGTGTGCACCTGCATGTGATTGTGTGTGTGAGAGAGTGTGAGAAACAAA
GTGTGAATGTGTGCATATGTGAGTGTGAGAGCATGTGTAAGTGCATGCGTGT
GTGTGGATGTGTGTTTGAGAGTATATGTGCACATGCATGTGATTGAGATAGA
GTGAGACAGTGTGCATATGTGAGTGATAACGTGTAAGTGCATGAGTGTGAGT
GTGCGTGGATGTGAGAGTATGTGTGCACATGCATGTGATTGTGTGTCTGAGAC
TGTGAGCATGTGTGTGTGGGTGCATGTGTATGTGGGTGCATGTTGTGTGTGTG
AATGTGTGTTAGAGCATGTGTGGGTGCATATGTGAGACTGCATGTGTGTGTGA
GTGCATGCATGTTTGGGAGACAGCATGTGTGGGTTCATGCATTNGAGCACGT
AGTGTGTCAGTGTGTGCATGTATCCCGNGTGNGNGNGNG~?fN
16122 2-22 (Reverse ]
CCCGGGoGATCATCTCTATACAAGTCATTTGCTAAGTTTTATGAAAGCCAGAG
AGAACAAATCATTCTAATAGATTGTGGAAAAGGTTTTATAGAAAAAGTGGGG
-119-
GGAAAACAGAGGCGTGACAATGCGGGTGTTTCAGGAAATGGTGTGACTACAG
TCTAGTGGGTGGGGAAGTGACCGAAAATGAGACTGAGTCTGGACTGAAAAGT
GACCTGAGTGACACACATAAAGGAACTGAAACGTAGCAATCAGAAACCGCG
GCGTCATGCTAACTTCTGTAACTCCAGCACCCAGCACAATTCCTCAGGCAAA
GCAGGCTCTCAGTAACGCCTGTGACGTTAACACATTCCTGAGAGGAACATGG
AGCCGCCGAGGAGCTGATGGAGAAAGCGGTGCACACAACTTCGCGTTTTGGA
AAGATAATCTTGGTCACTGTACAGAACAAACTGGAGTGGCAAGGACATGGAA
GACCTCCATCAGAA TTGG~~TTAATTTCA TCTATTATGTCCTA TTATGTC
CTAATGACAAGATTTTCCCCTGCAGGCACCAGCAJVV\ATCAAACTACAAATG
CCGGGCTAAACCAAGTCCAGAGAATTCCTGAGGTCCTGAGGACAGGGTCCCC
CTAAGTACTCCTCCTGCATTCATATCTTCTGTCTCAAGCCTGTGTTNCTTTTAA
ACACACACACACAACA CNGG~7TCCTTTCCCCACACTGGCCACACTTCACCG
TGCCTCAAAATGGCATGGAACCCCCCCCATGCTTTTTTCCCAAACATGCCATG
CACCTTCACACCACACCATTCCAGTT
161221-40(Forward)
CTAGAG*GATCTGTTTCTATTTAATACTTAGAGAATTGTAGGTTCTAGGTACT
CTGAAACAGCCACTAATTTCATTCCCTTGGCTTACCTATICCCTTGGATATAG
GTAAGACATTTCATATATTTGTATTTTGTGTGTGTGTGTGTGCATGTGTGTG
TGTGTGTCIGTCTGTCTGTCTGTCITGTGGCGCTTTAATATTATTCTGGCAT
TTTAGAATGGATAAATTTCTATAATTTACTCICCAGATC*CCCGGGTACC
-120-
65b9 4-34 (Fo rwa rd)
CTAGAG·GATCGCCGAGCGCCCCGGC.~~GGTAAGAACCTTGAAACAGCATCC
ACGCAAGAACAAAACGGCCATCAACATCGAATACATGAAAGCCAGCATCCG
GGCCAGGGTGGAGCACCCATTTCGCATCATCAAGCGACAGTTCGGCTTCGTG
AAAGCCAGATACAAGGGGTTGCTGAAAAACGATAACCAACTGGCGATGTTAT
TCACGCTGGCCAACCTGTTTCGGGCGGACCAAATGATACGTCAGTGGGAGAG
ATCTTGGCCCCTGCCCTCCTCTTAAATCGCCATCCCCTACCCCCAACACCTTA
AAAAAATGATAATAAAGTACATGAAGACAGTTTGAGAGCTTTAGGTTTCCCA
CTGAGGTTTGGAGCTTCTCTCATGGGAACCGGTCCCCAGGCTGCATTCACGAA
TTGCTCTCATCTCCATTCTCCCACAGGTTTGTTCTCCACCCGTACCCCCCACCT
CGCCCGGCTATCTTACTCCCTGCGATTTCTATAGGAAAAAGTGTGTTCTTGGC
AGGGCGTGGTGG~CATGCCTGTXATTCCAACACTTTGNGAGGN~~GGCKG
NCGGATCGAC
65b9 4-34 (Reverse)
CCCGGG' GATCCCTCTAGGCATTTGGGAGTGAGGGGTTCTGCTCCTCCTCAGC
TCTAACTCCGTGCTAGTGGGGGGAGAGACATAATAAACAAGTAAACAAATAC
ATATGATTTTTTACAAAAATTATAATAAGTTCTATGAAAGAAATAAAGCAGG
GAACTGAGGCAGAGGCAGCATTCTAGGATAGGTAGGATAGGTGATCAAAAG
TGGGCAATATTGCCTCTAGAGAGATGTGGCAGCAAGGACATTTTAAGTAAAG
GCAGACATGGCCAAGCCCTTAGGAGATACTAATGTGACTAGAATGAAGGGTC
-121-
CACAGGAAAGGTGAGTACAGGGTACGACTGAAAGCAGCTGGGTACATTGGG
CCTGACTCTAGAGGTCACAGCCAACAGAATAAGTACACAGTGCCTGATTTAG
TAGGAAAAAGGGAGCCATTGATGGCTTTTGAGCAAAGGAGAGACTATCAAA
GTTGTGCTTTAGGAACATTAATCTGGCCAGAGCATGTGTAGAATTAATTATTT
CAATCAA~TAAAAGGAAATGAAGCTG GGGCCAGGCTCAGTGGCT CATGCCTG
TAATTKCAGCACTCTGGGAGGCTT GAGGTGG~~GGNTCCTNAAA ~~~AATAC
TCCTTTTTN1TATTANGCCTTTC
6Sh9 1-9 (Forward)
CTAGAG'GATCAAAAGCACAGAAAGGTGTCCACTTCTTACCCTGTTGGAAGG
CACAAAGGATGGTTTAGAGGGAGGTATGTTTATGTCTGCCTCACTTATTGAAA
AATACATCTGTACTTATGCCCTCCACTTTCTCATCAACTATTTCTATGCATTCT
GGCTTCTlCI 111111111111111 IIIII GAGATGGAGTCTCACTCTGTCGCCC
AGCTGGAGTGCAGTGGCATGATCCTCCCACCTCAGCCACTTGAGTAGCTTGG
ACTACAGATG CGTACCACCATGCCTGGCAAA~CTTTTTAA GTTTTT
ATAGGGACAGGGTTTTGCATGTTGCCCAGGCTGGTCTCGAACTCCTGGGCTCA
AGCAGTCCACCTGCCTCAGACTCCCAAAGTGCTGGGATTACAGGTGTGAGTG
GATGTGCCTGGCCAGTTTCTAAGATGTTATGATATATAGATCACAAGGTCAG
GAGCTTGAGACCACCCTGACCAACATGGTGAAACCCCATCTCTATTAAAAAT
ACAAAAGAAAAATTAGCCCGGTGTGGTGGCGCATGCCTGTAATCCCAGCTAC
TCAGGAGGCTGAGGCAGGAGAATAGCTTGAACCCGGGAGGCAGAGGTTGCA
-122-
GTGAGCCAAGATC'CCCGGG
1460105-37 (Forward)
CTAGAG' GATCCCTCCATTTGGGGTCCCTGACTTCCCGCAACTCTGCTAAAGG
TAGTGTATTAACATCCACACAAAGCCCAGAAAAAAATGAACAAAGACTGAA
GCAAAATGTGCCTTTAGGCCAATC TCAAAAGAAACTTAAGAA CATTGGGGG~
TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGGTGGGGTTTTGTTGT
TGTTGTTTGTTTTTTTGAGACAAGGTTTCACTCTGTTGCCTAGGTTGGAGTGCA
GTGGCATGATC'CCCGGG
Appendix 8: STS primers designed around Dovel satellite repeats found in PAC
Marker Sequence(5' - 3') P ro du ct An nea ling
Size (bp) Temp. ('C)
265a141-3 (F)TGAAGAGCTGGCCTATCAGTC 177 55
(R)AAGTCTCCTGGCCACATTTTT
16122 1-40 (F)TGGCTTACCTATTCCCTTGG 174 55
(R)CCGGGGATCTGGAGAGTA
1460105-37' (F)TGTGCCTTTAGGCCAATCTC 163 ??
(R) GGATCATGCCACTGCACTC
"Unfortunately the Reverse pnmer of thesubclone 1460105-37 included part of the vector
whichmay account forthe lackofa product whenusedto analyzethe ui DNA.
· 123·
Appendix 9: PACsubclonesequence BLAST:"li an.a hlsis
203062·36<Fl
embIAL034343.17IHSI08C2 HumanD~A sequencefrom clone 108C2on chromosome
6pI2.1·21.1, complete
sequence[Homosapiens]
Length=130904
Score = 1029 bits (519), Expect= 0.0
Identities =5261527(99%), Gaps = 1/527 (0%)
Strand=PlusI Plus
203062·36CRl
emblAL034343.171HS108C2 Human DNA sequence from clone 108C2on chromosome
6p12.1·21.1, complete
sequence [Homo sapiens]
Length= 130904
Score=1025bits (517),Expect~ 0.0
-124-
Identities = 5261528 (99%), Gaps= 11528 (0%)
Strand> PlusI Minus
embjX68S51JECKUPRBS E.colilcup gene forintegral membrane protein
Length= 2367
Score= 163 bits (82), Expect= le-37
Identities = 82/82 (100%)
Strand =Plus 1Plus
8blAE0004521AE000452 Escherichia coliK-12MG1655section342of400ofthecomplete
genome
Length= 10700
Score= 155 bits (78), Expect= 2e-35
Identities =78178 (100%)
Strand = Plus 1Plus
gblLl03281ECOUW82E. coli; the region from 81.5to 84.5minutes
Length= 136254
-125-
Score' 155bits (78), Expect=2e-35
Identities = 7sn 8 (100010)
Strand=Plus I Plus
2653141-3 CFl
gb1ACOO5886.21ACOO5886 b240g16, complete sequence [Homo sapiens]
Length = 1340II
Score m 56.0 bits (28), Expect= Ie-05
Identities =40144 (90%)
Strand=PlusI Minus
emb1Z97 180.11HS203P18 Human DNA sequence from PAC 203Pl8 on chromosome
Xq27.I-Xq27.3.
contains CpG island,and polymorphic CArepeat
Length « 132470
Score ' 54.0 bits (27), Expect= 6e-05
Identities = 42/46(9I%), Gaps = 2/46 (4%)
Strand = Plus I Minus
· 126·
265a14 1-3fRl Nothing significant
16f222~22(F) Nothingsignificant
16£22 2-22(R)Nothingsignificant
16£221-40(F) Nothing significant
emblAL034343.l71HSI08C2 Human D~A sequence from clone IOSe2 on chromosome
6p12.1·21.1, complete
sequence [Homo sapiens]
Length~ 130904
Score~ 547 bits (276), Expect~ e-153
Identities ~ 309/325 (95%)
Strand = Plus I Minus
-127-
emb1AL034343.I7JHSI08C2 Human DNA sequence fromclone 108e2 on chromosome
6pI2.1-21.1, complete
sequence [Homo sapiens]
Length = 130904
Score = 674 bits (340), Expect = 0.0
Identities> 340/340 (100%)
Strand = Plus / Minus
emblAL034343.l 71HSI08C2 Human DNA sequence from clone 108e2 on chromosome
6p12.1-21.1. complete
sequence [Homosapiens]
Length= 130904
Score = 361 bits ( 182), Expect = 2e-97
Identities =182/182 (100%)
Strand == Plus I Minus
1460105-37 Nothing significant
-128-
Appendix 10: Snumik output for the I08c2 PAC clone full sequence.
The output inboldindicate severalseparate repeats whichalloccurasa single larger
complexrepeatregion. IIwasthis regionforwhichtheI08c2FULLI primerswere created.
>giI5931807!embIAL034343.17IHS108C2 Human DNA sequence from clone 108C2
trinu cleotide 1J9: 138 -cl ength 20 score 17
AACAACAACAACAACAACAA
tetranucleotide 3973 : 3985 -- length 13score 9
CCCTCCCTCCCTC
tetranucleotide 3990: 4009- length20 score 16
TCCTTCCTTCCTTCCTTCCT
trinucleotide 5226 : 5237 -e Iength 12score 9
AGGAGGAGGAGG
Dinucleotide 6158 : 6176 -e length 19 score 17
ACACACACACACACACACA
tetranucleotide 7102: 7115 -- length 14score 10
ATAAATAAA TAAAT
pentanucleotide 7272: 7289 -c length 18 score 13
AAATAAAATAAAATAAAA
Dinucleotide 8723: 8755 - length33 score31
ATATATATATATATATATATATATATATATATA
-129-
Dinucleotide 11881 : 11894 - length 14 score12
GAGAGAGAGAGAGA
pentanucleotide 13675 : 13688 -length l-sscore9
AA-\ GCAAA GCAAAG
tetra nuc leotide 14662 : 14736 -length 7S score 59
TTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTCTTTC
TTTCTTTTTCTTTCTTTCTTTCT
tetra nuclecride 14737 : 14765 -length 29 score 25
CCTTCCTTCCTTCCTTCCTTCCTTCCTTC
Dinucleotide 14768 : 14787 -length 20 score 18
TCTCTCTCTCTCTCTCTCTC
tetranucleetide 14788 : 14835 -length 4 8 score 44
CTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTCCTTC
Dinucleotide 14836 : 14912 - length 77 score 33
TCTCTCTCTCTCTCTCTCTCTCTCTCTCTTTCTCTCTTTCTCTCTTTCTCTC
TTTCTCTCTTTCTCTCTTTCTCTCT
tetranucleotide 14913 : 14929 -length 17 score 13
TTCTTTCTTTCTTTCTT
pentanuclectide22294 : 22312 - length 19 score 14
TTTTGTTTTGTTTTGTTTT
tetranuclectide 26718 : 26740 -length 23 score 12
- lJ O-
TITGTITGTIT GTICGTITGTIT
Dinucleotide 29477 : 29487 -. length 11score9
AGAGAGAGAGA
tetranu cleotide 30893 : 30915 -- length23 score 19
TITATITATITATITATITATIT
tetran ucleotide 33163 : 33177- length ISscore II
AATGAATGAATGAAT
pentanuc!eotide 33968: 33981 -- length 14 score9
TITIATITIATITI
Dinucl eotide 37953 : 37966 -- length 14 score 12
GTGTGTGTGTGTGT
tetranu cleotide 40200 :402 J2 - length 13 score9
TITCTITCTITCT
trinucleotide40434 : 40453 - length20 score 17
TICTICTICTICTICTICTI
pentanucl eotide 40725 : 40739 -. length15 score 10
AGGGGAGGGGAGGGG
trinucleotide 40755 : 40766 - length 12 score 9
GGAGGAGGAGGA
pentanucleotide 43320 : 43344 - length25 score 13
AAAACAAAACAAAAACAAAACAAAA
-131-
pentanuclectide 52428 : 52445 --l ength 18 score 13
lTITCTITICTITICTIT
tetranucleoride 53952 : 53979 -c length 28 score17
ATITATITATITATITAC ITATITATIT
trinucleotide 54272 : 54283 -- length 12 score9
ITAITAITAIT A
trinucleotide 56825 : 56838- length 14 score 11
ITGITGITGIT GIT
tetranucleotide59897 : 59911 --length 15score 11
TITATITATITATIT
trinucleotide 63337 : 63349 -length 13score 10
GAAGAAGAAGAAG
tetranucleotide 66349 : 66370 - length22 score 18
ITATITATITATITATITATIT
pentanucleotide 73277: 73295 -- length 19 score 14
TAAAATAAAATAAAATAAA
pentanucleotide 76547 : 76560 --l ength 14 score9
lTITGlTITGlTIT
pentanucleotide 81811 : 81824 - length 14 score9
CTGTGCTGTGCTGT
pentanucleotide 83986 : 83999 - length 14score 9
-132-
TlTfGTlTfGTITf
tetranuclecride 87559: 87573 --length 15 score II
-;TICTITCTITC1TI
pentanucleot ide91317 : 91346 ~. length 30 score 25
CAAAACAAAACAAAACAAAACAAAACAAAA
pentanucJeotide9I692 : 91724-- length33 score28
AAACAAAACAAAACAAAACAAAACAAAACAAAA
Dinucleotide 95163 : 95183-- length21score19
CTCTCTCTCTCTCTCTCTCTC
Dinucleotide 95185: 95200 - length16 score 14
ATATATATATATATAT
Dinucleotide 96248 : 96260 -- length 13score II
AGAGAGAGAGAGA
pentanucleotide 100016 : 100029 - length 14score 9
CTGAACTGAACTGA
tetranucleotide 104791 : 104803 -- length 13score9
TATITATITATIT
tetranucleotide 107121 : 107152 -vlength 32 score 28
AAACAAACAAACAAACAAACAAACAAACAAAC
tetranuclectide 108459 : 108489 - length 31 score 13
TTCATTCATTCACTCATTCACTCATTCATTC
- 133-
trinucleotide 110705 : 110723 -- length 19score 16
TAATAATAATAATAATAAT
Dinucleotide 112705 : 112717 - length13 scoreII
TCTCTCTCTCTCT
Dinucleotide 112720 : 112746 --l ength 27 score 18
ACACACACACACACGCACACACACACA
pentanucleotide 11 4775 : 114788- length14 score9
TATAGTATAGTATA
pentanucleotide 120358 : 120372-clength 15 score 10
CAATTCAATTCAATT
retranucleonde 122465 : 122478 -length 14 score 10
AAATAAATAAATAA
tetranuclectide 126166: 126209 -- length44 score26
TCCCTCCCTCCCTCCCTTCCTCCATCCCTCCCTCCCTCCCTCCC
trinucleotide 127561 : 127574 - length 14 score 11
TCTTCTTCTTCTTC
-62-
Gel 1
+ • I 2 3 4 5 6 7 8 9 101 1
Gel )
+ 23 24 25 26 27 2829 30 31 32
Gel 2
I. 1-10 7. 61-70 13. 121-130 19. 181-190 25. 241-2S0 3 1. 301-310
2. 11-20 8. 71-80 14. 131-140 20. 191-200 26. 251-260 32. 311-321
3. 21-30 9. 81-90 IS. 141-ISO 21. 201-210 27. 261-270
4. 31-10 10. 91-100 16. ISI-160 22. 211-220 28. 271-280
S. 41-50 II . 101-110 17. 161-170 23. 221-230 29. 281-290
6. SHO 12. 111-120 18. 171-180 24. 231-240 30. 291-300
+ 101 102 103 104 lOS 106 107 108 109 110
flgy[ill.; Plate pool screening of the PAC "Plate Pools" with the marker 8SSR. Note
that the marker amplified a fragment in 101, indicating that the PAC of interest
is in that plate . + = positive control (human genomic DNA), - = negative
control (dH,O) .
Gel I
-64-
Gel2
-lOO-
JOO-
259-
200-
100-
Gel 3 Gel4
259-
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